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The objective of this body of research was to (1) survey current self-management 
skills and treatment knowledge in patients with phenylketonuria (PKU) and (2) evaluate 
self-efficacy, patient activation, dietary adherence, and blood phenylalanine (Phe) levels 
in individuals with PKU before and after a 6-month motivational interviewing (MI) 
intervention. 
Patients with PKU aged 7-30 years (n=43) completed one of three age-specific 
self-management questionnaires during standard metabolic clinic appointments and were 
invited to participate. Separately, patients with PKU aged 7-35 years (n=31) participated 
in a 6-month intervention including phone-based MI, goal setting, and a monthly 
summary. Participants completed stage of change (SOC), self-efficacy, patient activation, 
and food frequency questionnaires online and obtained monthly blood Phe samples. 
Demographic data were collected from the electronic medical record. We considered 
p<0.01 as significant when analyzing aim 1 and p<0.05 as significant when analyzing aim 
2.  
Participation in self-management behaviors and treatment knowledge did not 
increase with age for most measures (p>0.01 for all) with only approximately half of 
adults meeting clinical recommendations. Higher self-management skills and treatment 
knowledge were not associated with lower blood Phe levels (R2=0.249, p=0.025), which 
may reflect the small sample size. 
 
 Most participants were in the action/maintenance SOC for PKU treatment 
behaviors during the 6-month MI intervention. Self-efficacy significantly increased from 
baseline (7.4±1.9) to month 6 (8.6±1.3) among adolescent and adult participants 
(p=0.002). There was no increase in patient activation (p=0.10) or dietary adherence, 
though most (n=28/31) reported adherence to medical formula at baseline. Pre-
intervention blood Phe slope for all participants (β=0.71) was not significantly different 
from the intervention slope (β=0.26, p=0.13). Higher baseline SOC (β=-61.6, p=0.005) 
and increasing self-efficacy (β=-64.5, p<0.001) were associated with a decreased blood 
Phe slope. 
Self-management skills were lower than clinically recommended and did not 
consistently increase with age. We demonstrated a significant increase in self-efficacy 
with MI and, in turn, higher self-efficacy was associated with a reduction in blood Phe 
levels. Our results suggest strategies to support self-management and increase motivation 
for behavior change are necessary. Phone-based MI is feasible with a PKU population has 







TABLE OF CONTENTS 
ABSTRACT ....................................................................................................................... iii 
LIST OF TABLES ............................................................................................................ vii 
LIST OF FIGURES ......................................................................................................... viii 
LIST OF ABBREVIATIONS ............................................................................................ ix 
ACKNOWLEDGMENTS .................................................................................................. x 
Chapters 
 
1    INTRODUCTION .................................................................................................. 1 
1.1 References ......................................................................................................... 7 
2    SELF-MANAGEMENT SKILLS AND TREATMENT  KNOWLEDGE IN 
PATIENTS WITH  PHENYLKETONURIA ....................................................... 11 
2.1 Abstract ........................................................................................................... 11 
2.2 Introduction ..................................................................................................... 12 
2.3 Methods ........................................................................................................... 15 
2.4 Results ............................................................................................................. 20 
2.5. Discussion and Conclusion ............................................................................ 29 
2.6 Acknowledgements ......................................................................................... 36 
2.7 References ....................................................................................................... 36 
3    PHONE-BASED MOTIVATIONAL INTERVIEWING TO  INCREASE 
SELF-EFFICACY AND PATIENT  ACTIVATION IN INDIVIDUALS 
WITH PKU ........................................................................................................... 42 
3.1 Abstract ........................................................................................................... 42 
3.2 Introduction ..................................................................................................... 43 
3.3 Methods ........................................................................................................... 47 
3.4 Results ............................................................................................................. 53 
3.5 Discussion and Conclusion ............................................................................. 61 
3.6 Acknowledgements ......................................................................................... 69 
3.7 References ....................................................................................................... 69 
4    A NOVEL APPLICATION OF MOTIVATIONAL  INTERVIEWING TO 
IMPROVE TREATMENT  ADHERENCE IN PHENYLKETONURIA ............ 77 
 
 4.1 Abstract ........................................................................................................... 77 
4.2 Introduction ..................................................................................................... 78 
4.3 Methods ........................................................................................................... 82 
4.4 Results ............................................................................................................. 89 
4.5 Discussion ....................................................................................................... 94 
4.6 Acknowledgements ....................................................................................... 101 
4.7 References ..................................................................................................... 102 
5    CONCLUSION ................................................................................................... 110 
5.1 References ..................................................................................................... 114 
Appendices 
 
A    COMPOSITION AND CODING FOR SELF-MANAGEMENT  SKILLS 
AND TREATMENT KNOWLEDGE SCALES ................................................ 117 
B    STAGE OF CHANGE QUESTIONNAIRE ....................................................... 120 
C    COMPARISON OF ORIGINAL SELF-EFFICACY SCALE TO  REVISED 
COPY USED IN THE CURRENT STUDY ...................................................... 123 








LIST OF TABLES 
Table Page 
 
2.1 Clinically Recommended Self-Management Skills by Age Group ...................... 17 
2.2 Demographic and Treatment Data for Participants with Phenylketonuria by 
Age Group Presented as Mean±SD and Frequency .............................................. 23 
2.3 Number of Respondents Reporting Self-Management Behaviors and 
Treatment Knowledge in a Cohort of Patients with Phenylketonuria .................. 25 
2.4 Univariate Spearman Rank Order Correlations between Presurvey Blood 
Phenylalanine Levels and Self-Management Indicators in Participants Aged 
10–30 Years .......................................................................................................... 27 
2.5 Comparison of Unadjusted Presurvey Mean Phenylalanine (Mean±SD) by 
Treatment Knowledge and Use of Dietary Phenylalanine Monitoring in 
Participants Aged 10–30 Years ............................................................................. 28 
3.1 List of Behavioral Targets for Stage of Change Questionnaire ............................ 49 
3.2 Demographic and Baseline Treatment Information for Participants with 
PKU, Presented as Median (IQR) or Frequency ................................................... 55 
3.3 Baseline Stage of Change for Three Behavioral Domains ................................... 57 
3.4 Individual Self-Efficacy Scores by Question for Participants with 










LIST OF FIGURES 
Figure Page 
 
2.1. Study Enrollment Process ..................................................................................... 21 
2.2.  Boxplot of Presurvey Mean Phenylalanine Levels by Age Group ....................... 22 
2.3.  Spearman Rank-Order Correlations between Presurvey Mean Phenylalanine 
Concentrations and Scale Variables in Participants Aged 10-30 Years ............... 30 
3.1.  Flow Chart of Participant Recruitment, Enrollment, and Retention ..................... 54 
3.2.  Patient Activation Levels for Participants at Baseline, Month 3, and Month 6 .... 59 
3.3.  Predicted Means ± Standard Error for Patient Activation (A) and Self-
Efficacy (B) for All Participants from Baseline to Month 3 and Month 6 ........... 62 
4.1.  Monthly Summary Emailed to Participants .......................................................... 85 
4.2.  Median Distribution of Protein Intake for All Participants .................................. 91 
4.3.  Predicted Slope in Blood Phenylalanine (Mean ± Standard Error) 6 Months 
Pre-intervention and During the Intervention ....................................................... 93 
D.1.  Summary Sheet Emailed to Each Participant Monthly Prior to the Phone-








LIST OF ABBREVIATIONS 
BH4 tetrahydrobiopterin 
BMI body mass index 
CV coefficient of variation 
EF executive functioning 
IEP individualized education program 
IQR interquartile range 
MI motivational interviewing 
PAH phenylalanine hydroxylase 
PAM patient activation measure 
Phe phenylalanine 
PKU phenylketonuria 
SD standard deviation 










This dissertation was made possible through the contributions of many 
individuals. I want to acknowledge the Division of Medical Genetics for allowing me to 
conduct research with the Utah Metabolic Clinic, and our patients for their willingness to 
participate. I would especially like to thank Sharon Ernst, Ashley Vollenweider, and 
Chelsey Clegg for assisting with study development, data collection, and recruitment. I 
also owe a special thanks to Nicola Longo, who supported my research, both 
professionally and financially. I have been fortunate to study under several prodigious 
mentors, including Deborah Bilder, Nicola Longo, and Sharon Ernst. I would also like to 
extend my deepest appreciation to my doctoral committee, Jessica Jones, Deborah Bilder, 
Maureen Murtaugh, Lisa Gren, and Joseph Stanford, for their time, expertise, and 
feedback, which greatly contributed to the quality of my education. Lastly, I would like to 













Chronic disease is pervasive. It is the leading cause of death worldwide, predicted 
to affect 157 million Americans by 2020, and contributes a substantial burden to the 
current health care system [1, 2]. Public health and health care systems were originally 
designed to address acute or infectious diseases and are not equipped to address the 
differing needs of chronic disease management [3-5]. Chronic disease management is, in 
many ways, more complex than acute management, in which the patient’s role is 
generally passive. Chronic disease management generally requires both medical and 
lifestyle interventions, and it relies heavily on the patient’s ability and willingness to 
follow medical recommendations away from the hospital or outpatient clinic [4].  
Treatment nonadherence is a common and costly phenomenon among individuals 
with chronic conditions [6-9]. Adherence generally refers to how well treatment 
recommendations are followed and implies an agreement with recommendations 
between clinician and patient [10]. However, placing the burden of following treatment 
recommendations solely on patients also places blame of poor adherence on the patient 
for lack of self-management skills. Poor treatment adherence does not necessarily reflect 
a careless or unmotivated patient, but implies current interventions and health care 
systems are inadequate to facilitate improved adherence [4, 11]. The Chronic Care 




of care for chronic illness [4].  
A key component of the CCM is supporting self-management, which refers to 
changes in the health system to encourage patient self-management behaviors [4]. This 
has been supported in several reports, especially in the setting of appropriate transition 
from childhood to adulthood [11-13]. Rather than focusing on standard education 
practices that may increase knowledge but not necessarily behavior, the CCM suggests 
focusing on perceived confidence and skills to manage the disease [4]. Strategies to 
support self-management include goal setting and problem solving with routine care and 
use of self-management programs for disease-specific education, which have been shown 
to improve self-management [14-17]. Ultimately, this model aims to engage patients in 
their care, set attainable and specific goals, identify potential barriers, and help patients 
to develop solutions to overcome those barriers.  
In the context of chronic illness, the term self-management refers to one’s ability 
to manage the physical and psychological symptoms and implement necessary 
treatments and lifestyle changes to maintain an acceptable quality of life [18]. Therefore, 
comprehensive self-management encompasses more than medical and behavioral 
management, also including role and emotional management [19, 20]. In addition to 
organizing daily treatments, individuals and families may need to adapt life roles and 
develop coping strategies to accommodate the chronic illness [19].  
Phenylketonuria (PKU), one of the conditions detected on newborn screening, is 
an often overlooked condition in discussions about chronic disease management. 
Individuals with PKU are an exemplar of the difficulties associated with improving self-




Additionally, this condition encompasses the challenges surrounding transition from 
childhood to adulthood for youth with special health care needs and designing strategies 
to work with cognitive and/or executive deficits [12].  
PKU is a rare disorder with a prevalence of approximately 1 in every 10,000 
people [21]. PKU results from phenylalanine hydroxylase deficiency causing impaired 
phenylalanine (Phe) metabolism. Untreated PKU results in profound intellectual 
disability [21]. However, the vast majority of individuals with PKU living in the United 
States are diagnosed on newborn screening and dietary treatment is initiated at birth. A 
protein-restricted diet and supplemental medical formula are prescribed to maintain 
blood Phe levels within 120-360 μmol/L throughout life for optimal outcomes [22, 23]. 
However, many patients exceed the recommended blood Phe range and experience 
subtle intellectual and/or executive deficits and psychiatric symptoms compared to 
healthy controls [24-28]. 
The treatment for PKU is complex and time consuming. The diet requires 
knowledge of the protein content of foods and the ability to track protein intake and plan 
meals to meet a specific protein goal. One study reported two major sources of stress for 
families managing PKU were planning and preparing low protein meals and the social 
ramifications of the diet [29]. In addition to a highly restrictive diet (e.g., an adult may 
only tolerate 5-10 grams protein per day), patients are prescribed a medical formula free 
of phenylalanine, which clinicians recommend to consume in multiple servings daily 
[30]. This formula is costly, difficult to obtain through insurance, and, for some, 
unpalatable [31]. Additionally, patients are faced with frequently obtaining blood 




metabolic clinic appointments.  
The current model for the treatment of PKU, at least in some centers, may not 
adequately support self-management [10, 32, 33]. This is corroborated by poor treatment 
adherence reported in this population [34, 35] and a perceived paucity of knowledge 
among patients with PKU [36]. From a clinical perspective, treatment adherence and 
metabolic control appear to be better in those who slowly acquired self-management 
responsibilities, starting at a young age, with continued support from caregivers 
throughout adolescence compared to those experiencing a rapid transition of self-
management responsibilities, typically occurring during adolescence. Strategies to 
encourage self-management starting at a young age are recommended to facilitate timely 
and appropriate transition of responsibility to the child [37].  
The patient-provider relationship is also a critical component of care. Positively 
perceived relationships with medical providers have been associated with self-care 
behaviors in patients with diabetes [38]. The current clinical system often supports direct 
questioning and giving advice [39]. In other populations, these techniques have been 
shown to increase resistance and may negatively impact patient-provider communication 
[40-42]. Additionally, inborn errors of metabolism, such as PKU, are rare disorders with 
few clinics specializing in their care [43]. Therefore, patients may not have access to an 
alternative clinic or provider, making it even more critical to maintain rapport. Negative 
relationships with providers may contribute to loss to follow up. This is a common 
phenomenon among adults with PKU with an estimated 77% of adults with PKU not 
receiving treatment from a metabolic center in 2012 [44], which increases the likelihood 




Successful self-management involves more than the individual; the ability to 
engage in necessary behaviors must be placed in context of social and environmental 
settings [11]. For individuals with PKU, this includes individual factors, social and 
economic factors, treatment options, and health care system factors [44]. These might 
include cognitive and/or executive functioning skills, family support, access to medically 
necessary treatments, such as medical formula and low protein foods, and access to a 
metabolic center [31, 44]. While a system change to support self-management in a larger 
context is needed, we must also address individual motivation and ability, which has 
been relatively unexplored in this population.  
Strategies to support self-management are needed for patients of all ages with 
PKU. It may be particularly beneficial during preadolescence and adolescence, as these 
developmental periods involve dramatic increases in independence and ability to 
participate in self-care [37]. While it may be assumed that adult patients should already 
have the required skillset to manage the dietary treatment, disease related stressors 
change with age, which may require development or review of skills/knowledge to 
adequately cope with new challenges [36]. However, we must be cautious, as the 
targeted outcomes of self-management are often derived from the medical team, and may 
not be congruent with the values of the individual or family [11]. 
Motivational interviewing (MI) with goal setting may be well suited to facilitate 
improved self-management [42, 46]. MI is a patient-centered, directive counseling style 
aimed to resolve ambivalence about change and elicit one’s personal motivation for 
change. While self-management does not merely involve the “self,” the patient is a 




providers to survey personal goals and values, which may refocus the goal of self-
management to reflect the patient’s desired outcomes [42]. Additionally, coupling goal 
setting and action planning with MI provides the opportunity to assess the context of 
one’s ability to engage in targeted self-management behaviors. Providers can assist with 
problem solving, which is a skill that may be impaired in patients with PKU [47, 48]. 
Additionally, MI in conjunction with goal setting/action planning may be feasible to 
incorporate into an outpatient metabolic clinic setting.  
Poor treatment adherence is prevalent among individuals with chronic illness, 
including those with PKU, which results in intellectual and behavioral sequelae. Chronic 
disease self-management is complex and involves environmental and social factors in 
addition to the individual. Strategies to support development of self-management skills 
are needed in PKU care and have been largely unexplored. MI with goal setting offers a 
means to engage the patient, understand their goals and values, and barriers to change. 
While this approach does not directly address environmental factors, it allows providers 
gain an understanding of individual barriers to treatment.  
Evaluation of current self-management skills and methods to enhance self-
management and treatment adherence would be beneficial to improve long-term 
outcomes in a PKU population. Additionally, if proved effective, the premise of the 
proposed intervention could be applied to other chronic diseases and could be 
transferrable to other metabolic clinics working with a variety of conditions diagnosed 





1. Describe self-reported treatment knowledge and participation in age-appropriate 
self-management skills in patients with PKU.  
2. Evaluate changes in patients’ reported stage of change, self-efficacy, and 
patient activation to improve self-management behaviors before and after a 
motivational interviewing (MI) intervention.  
3. Evaluate changes in blood phenylalanine levels and adherence to dietary 
protein and medical food prescriptions before and after a motivational 
interviewing intervention. 
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SELF-MANAGEMENT SKILLS AND TREATMENT 
 





To describe patient-reported self-management behaviors and treatment 
knowledge in patients with phenylketonuria and explore how these correlate with blood 
phenylalanine (Phe).  
2.1.2 Methods 
Participants (n=43) completed an age-specific questionnaire (7-12, 13-17, and 18-
30 years) including questions used to construct three scales as overall measures of self-
management. Blood Phe levels collected 12 months prior to enrollment were included. 
Data analysis included descriptive statistics, Spearman correlations, Mann-Whitney U 
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test and multivariate linear regression. Significance defined as p<0.01.  
2.1.3 Results 
Participation in self-management behaviors and treatment knowledge did not 
increase with age for most behaviors (p>0.01). Approximately half of adults met clinical 
recommendations for self-management behaviors. Treatment knowledge was associated 
with increased participation in corresponding behaviors (p<0.005 for all). Higher self-
management skills and treatment knowledge were not associated with lower blood Phe 
levels after controlling for number of blood samples (R2=0.249, p=0.025), which may 
reflect our small sample size.  
2.1.4 Conclusion 
Promotion of self-management skills is important for patients with PKU and may 
help achieve lower blood Phe levels. Overall, participation in self-management behaviors 
was lower than clinically recommended. More research is needed to evaluate methods to 
improve self-management.  
2.1.5 Practice Implications 
We recommend using the surveys or a similar tool as a checklist in a clinical 
setting to facilitate discussion of self-management skills. 
2.2 Introduction 
Phenylketonuria (PKU) is an inborn error of metabolism characterized by a 
deficiency of the enzyme phenylalanine hydroxylase (PAH), which converts the amino 
acid phenylalanine (Phe) into tyrosine. PAH deficiency results in elevated blood and 




exposure during infancy and early childhood leads to profound intellectual disability, 
severe behavioral disturbance, and seizures [2, 3]. Since 1964, newborn screening 
programs in the US identify PKU at birth; severe neurologic impairment is prevented 
through early initiation of a lifelong Phe-restricted diet and supplemental medical 
formula. Dietary treatment is designed to reduce blood Phe levels to a therapeutic range 
(120-360 μmol/L) [4, 5] in order to decrease cerebral Phe concentrations. It is widely 
accepted that tight control of blood Phe levels throughout life is strongly associated with 
improved cognitive outcomes [6, 7]. 
The treatment for PKU involves three primary components: 1) monitoring dietary 
Phe or protein intake (as a proxy for Phe) [8]; 2) supplementing with a Phe-free protein 
medical formula to prevent protein malnutrition and improve satiety [9, 10]; and 3) 
testing blood Phe regularly at home via finger stick. The recommended amounts of 
dietary Phe and medical formula are based on blood Phe levels, growth, and clinical 
status [11], while the recommended frequency of blood Phe testing varies from weekly 
to monthly according to age, adherence to treatment, and blood Phe levels.  
An adjunct to a Phe-restricted diet is treatment with tetrahydrobiopterin (BH4), a 
cofactor to the PAH enzyme, which facilitates PAH folding and stabilizes enzyme 
activity [12]. Many individuals with PKU taking BH4 have reduced blood Phe levels and 
increased tolerance to dietary Phe [13]; however, only 40-60% of patients are responsive 
to BH4 therapy [12, 14].  
Successful implementation of a Phe-restricted diet requires a variety of skills and 
performing multiple tasks throughout the day. The individual must be able to calculate 




stay within a prescribed daily Phe/protein goal; keep detailed food records; prepare and 
drink medical formula daily; collect regular blood samples via finger sticks; and set and 
keep regular appointments with a metabolic clinic [15, 16]. Therefore, the treatment for 
PKU requires ongoing self-management from the patient and/or family.  
Self-management describes behaviors aimed to prevent or reduce the impact of 
illness on one’s health [17, 18]. Supporting patient development of self-management 
behaviors is becoming increasingly recognized as a critical component of primary and 
specialty care clinics [17, 19, 20]. Increased self-management behaviors have been 
associated with reduced morbidity in a variety of chronic diseases and with decreased 
health care utilization in children and adults [21, 22], including for PKU, with improved 
metabolic control found in patients who assumed personal responsibility for management 
of their condition [23]. 
Cognitive and executive functioning (EF) skills impact the ability to engage in 
self-management behaviors. EF skills facilitate nonstimulus driven control of behavior 
and emotion for self-regulatory actions [24]. These skills continue to develop well into 
the second decade of life [25] and include impulse control, mental flexibility, working 
memory, planning, attention, and self-monitoring [26]. EF abilities are positively 
associated with self-management skills in other chronic diseases managed with dietary 
treatment, such as diabetes [24, 27, 28].  
While early and continuous treatment prevents severe intellectual disability in 
PKU, subtle deficits in intelligence and executive skills, and increased emotional and 
behavioral concerns are frequently reported in individuals with PKU compared to 




levels and variability in blood Phe levels; greater mean and variation in Phe are 
associated with increased EF difficulties [6, 34]. Deficits in EF may also impair the 
ability of an individual with PKU to effectively manage a Phe-restricted diet, including 
restricting intake of high Phe foods, following a recipe or remembering to drink medical 
formula. 
Preadolescent evaluation and promotion of self-management skills are 
particularly important in patients with PKU, considering the multiple behaviors needed 
for successful treatment implementation and the risk of cognitive and EF deficits 
associated with inadequate adherence to Phe restriction. The objectives of this cross-
sectional study were to evaluate patient-reported self-management behaviors and 
knowledge in a cohort of patients with PKU and to explore how these correlate with 
blood Phe levels.  
2.3 Methods 
2.3.1 Participants 
Study participants were English-speaking individuals aged 7-30 years diagnosed 
with PKU on newborn screening and treated since birth. All participants were receiving 
treatment at the Utah Metabolic Clinic and attended an outpatient clinic visit during the 
study enrollment period (July 2013-July 2014). Exclusion criteria included intellectual 
disability (IQ <70), pregnancy (current or within 12 months prior to enrollment), 
concurrent participation in clinical trial(s), and hyperphenylalaninemia not requiring 
dietary treatment. Pregnancy was added as an exclusion criteria midway through the 
study, and pregnant participants who had previously consented were excluded from data 




impairment were invited to participate. Eligibility for an individualized education 
program (IEP), a written statement for each child with a disability specifying modified 
academic and functional goals [35], was used as a marker for learning impairment and/or 
EF deficits. The University of Utah Institutional Review Board approved this study and 
written consent – and child assent, if appropriate – was obtained for all participants. 
2.3.2 Instrument Development 
We developed three age-specific questionnaires (7-12 years, 13-17 years, and 18-
30 years) to evaluate patients’ current self-management behaviors and treatment 
knowledge. The basis of the survey content was the PKU Self-Management Timeline 
[16] with additional self-management goals defined by our clinic (Table 2.1). The 
recommended skills for each age group were based on Piaget’s model of cognitive 
development [16]. 
We formulated the questionnaires’ content standards using expert review from 
clinicians experienced in treating patients with PKU [36, 37]. We conducted a pilot study 
and cognitive interviews to assess cognitive standards, referring to the respondents’ 
ability to understand and respond to the questions [36]. Five patients with PKU piloted 
the questionnaires to identify questions requiring clarification and responses not fitting 
question intent. We conducted cognitive interviews with three staff members familiar 
with the PKU diet. They were asked to paraphrase each question in their own words to 
demonstrate their understanding of the question. Question wording was revised after 
assessment of content and cognitive standards. In July 2013, the questionnaire was 





Table 2.1. Clinically Recommended Self-Management Skills by Age Group 
Age group Self-management skills 
  
7–12 years Prepare and consume medical formula with decreasing supervision 
Identify high and low Phe/protein foods 
Weigh/measure foods regularly 
List food items on food records 
Know target blood Phe values 
Collect blood Phe samples via finger sticks with supervision 
  
13–17 years Prepare and consume medical formula with little supervision 
Independently manage daily dietary Phe/protein intake 
Independently keep food records 
Know target and recent blood Phe values 
Independently collect blood Phe samples via finger sticks 
  
18–30 years Independently manage all aspects of treatment: 
Prepare and consume medical formula 
Manage daily dietary Phe/protein intake 
Schedule and attend clinic appointments 
Refill medical formula and/or medication prescriptions 
Collect regular blood Phe samples via finger sticks 
  




2.3.3 Blood Phenylalanine Levels 
Presurvey Phe levels were reported as the mean for all blood Phe levels obtained 
during the 12 months prior to enrollment. Variation in blood Phe was measured as the 
coefficient of variation (CV), which is the standard deviation normalized to the mean 
(SD/mean*100). Blood Phe levels were obtained and measured using two methods as 
standard of care at ARUP Laboratories in Salt Lake City, UT: 1) dried blood spots on 
filter paper obtained between clinic appointments were analyzed using tandem mass 
spectrometry (MS/MS) without chromatographic separation and 2) quantitative plasma 
amino acids collected during clinic appointments were analyzed using quantitative liquid 
chromatography and MS/MS (aruplab.com). 
2.3.4 Data Collection from Patients 
Patients with PKU treated at our center are scheduled for regular clinic 
appointments every 6-12 months. Eligible participants were identified during weekly 
pre-clinic rounds. All patients were provided with the age-appropriate questionnaire 
upon arrival in the outpatient metabolic clinic once per year as a standard of care. 
Consent was obtained after questionnaire completion; only data from patients who 
consented were used in the analysis. All patients, including individuals less than 18 years 
of age, were instructed to complete the questionnaire with limited or no assistance. 
Caregivers were advised to clarify questions, if needed, but not to provide the answer. 
Four patients required assistance from a dietitian to answer the questionnaire. After 
completion, questionnaire responses were discussed with the patient and family in clinic 




2.3.5 Data Analysis 
Questionnaire responses were summarized using descriptive statistics: continuous 
variables were reported as mean ± standard deviation, and categorical variables were 
reported as frequencies. Differences between age groups were assessed using one-way 
ANOVA for continuous variables and Fisher’s exact test for categorical variables.  
Three scales were created a priori to evaluate the overall degree of participation 
in self-management behaviors and treatment knowledge (Appendix A). The behavior 
scale included two questions, each coded as 1 if the respondent indicated participation in 
age-appropriate behaviors for preparing medical food and collecting blood samples via 
finger stick (Table 2.1), 0.25-0.75 if done with some level of assistance (each 0.25 
increase represented a questionnaire response option with higher scores reflecting greater 
independence), or 0 if not done by the respondent. The treatment knowledge scale 
included three questions coded as 1 or 0, respectively, for the presence of, or absence of, 
correct PKU self-care knowledge (knowing one’s formula prescription, dietary 
Phe/protein prescription and target blood Phe level range). Responses within 25% of 
medical formula and dietary Phe/protein prescriptions as recorded in the medical record 
were coded as 0.5 for the knowledge scale. The individual scales were summed to create 
the behavior and treatment knowledge scale for an overall measure of self-management. 
Higher scores correspond to higher levels of self-management behaviors and/or 
treatment knowledge. There were some additional questions about dietary protein 
monitoring that we did not include in the scales because these questions differed across 
the age groups. 
We examined the correlation between the self-management scales and presurvey 




correlation coefficients. We also examined correlation for individual questions about 
self-care behaviors. The Mann-Whitney U test was used to evaluate differences in pre-
survey Phe levels by individual questions about treatment knowledge (coded as yes/no). 
We excluded patients under 10 years for these analyses because parents have greater 
control of their treatment. We used multivariate linear regression to evaluate the 
association between scale variables and presurvey Phe after controlling for potential 
confounders. Statistical analyses were performed using Stata 13.0 (StataCorp, College 
Station, TX). Significance was defined as a two-sided p value with alpha of 0.01 to 
account for multiple comparisons and reduce the risk of type I error. 
2.4 Results 
During the study period, 61 patients attended clinic and 58 individuals completed 
the self-management questionnaire; 52 of whom were invited to participate in the study 
and provided consent. Nine participants were excluded after signing consent, leaving 43 
patients for analysis (Fig. 2.1). There were no differences in age, sex, or medical food 
intake in those excluded after obtaining consent (data not shown).  
All participants included in statistical analyses had been prescribed a protein-
restricted diet with supplemental medical formula. The majority (82%) of participants 
receiving adjunct treatment with BH4 were 7-12 years of age despite all patients being 
offered a trial of BH4. Presurvey Phe levels increased with increasing participant age, as 
frequently reported in patients with PKU (Fig. 2.2, Table 2.2). One participant did not 
have a record of blood samples collected during the 12 months prior to enrollment. 
Approximately 26% of participants had some degree of learning impairment 





Figure 2.1. Study Enrollment Process
Eligible patients seen in clinic 
from July 2013 to July 2014 
(n=61) 
Patients consented (n=52) 
Initial eligibility identification 
(n=84) 
Patients with PKU in the 
University of Utah Metabolic 
Clinic database (n=183) 
Excluded (n=9) 
∙ Did not complete survey (n=3) 
∙ Inadequate time for informed 
consent during clinic (n=4) 
∙ Pregnant (n=2) 
Excluded (n=99) 
∙ Moved (n=26) 
∙ Age criteria (n=68) 
∙ Intellectual disability (n=4) 
∙ Spanish speaking (n=1)  
Excluded (n=23) 
∙ Were not seen in clinic during 
enrollment period 
Patients included in analysis 
(n=43, 51% of eligible patients) 
Excluded (n=9) 
∙ Concurrent participation in 
clinical trial(s) (n=6)  
∙ Pregnant (n=2) 





Figure 2.2.  Boxplot of Presurvey Mean Phenylalanine Levels by Age Group (N=42). 
Boxes indicate 25th and 75th percentile, lines within each box represent 
the median, and the reference line is the upper limit of the therapeutic 




Table 2.2. Demographic and Treatment Data for Participants with Phenylketonuria by 











Age (years) 14.6±5.9 9.6±2  16.3±1.6 22.4±3.6  
Presurvey mean Phe (μmol/L)  464±259 327±222 595±193 612±254 0.001 
Presurvey Phe variation (%)a 41.2±21.3 45.3±20.8 30±15.7 46.3±25.9 0.36 
Number of blood samples over 
prior 12 months 
7.0±4.5 8.8±4.6 5.1±3.4 5.2±4 0.03 
Number of food records over 
prior 12 months 
3±3.5 4.2±4.2 1.6±2.3 1.8±1.8 0.07 
Overweight/obeseb 17  4 5 8 0.01 
Female 23 12 4 7 0.52 
Regular intake of prescribed 
medical food 
39 20 10  9 0.36 
BH4 treatment 17 14 3 0 <0.001 
IEP eligiblec 11 5 4 2 0.73 
Note. BH4, tetrahydrobiopterin; BMI, body mass index; IEP, individual education 
program; Phe, phenylalanine; SD, standard deviation 
 
aPresurvey Phe variation measured as coefficient of variation (SD/mean*100) 
 
bFor participants <18 years of age, overweight defined as BMI >85th and <95th percentile 
on age- and gender-specific growth charts; obesity defined as BMI >95th percentile. Data 
source: [37, 38]. For adults, overweight defined as BMI of 25-29.9; obesity defined as 
BMI ≥30. 
  
cIEP refers to participants currently or previously eligible for an IEP in school as an 
indicator of learning impairment. 
  
One-way ANOVA used to determine statistical difference among age groups for 
continuous variables; Fisher’s exact test used for categorical variables. 





for an IEP but did not have one in place. Age, presurvey Phe levels, and self-
management scales did not differ significantly between those with an IEP and those 
recommended an IEP (data not shown); therefore, they were combined into one group. 
2.4.1 Self-Management Skills  
The primary improvement in self-management with increasing age was 
independent formula preparation (Table 2.3), and most adults reported the correct 
formula prescription and target blood Phe range. However, few (n=3) adults reported 
following the clinical guidelines for either medical formula preparation (Table 2.3) or 
frequency of blood samples (recommended monthly). Participation in related behaviors 
was higher, as most adolescents (n=7) consumed their formula ≥3 times daily as 
recommended [38] and most adults (n=8) independently refilled medical formula(s) 
and/or medication(s). 
The majority (n=16) of adolescents and adults reported using one or more 
reminder strategies to collect blood samples. The frequency of blood samples over the 
last year was higher for participants who reported a reminder strategy compared to those 
without reminders (6.3±0.9 and 2.3±0.7 samples, respectively, p=0.010). 
Dietary Phe/protein monitoring and knowledge did not increase with age (Table 
2.3). Nearly all (n=20) participants 7-12 years of age correctly identified the Phe content 
of a list of foods as either high or low. Fourteen participants knew how to operate a gram 
scale and 7 reported regularly weighing/measuring their own foods. Most adolescents did 
not know their dietary Phe goal, but over half (n=7) reported the ability to independently 
plan meals to meet their dietary Phe/protein prescription if eating away from home. 





Table 2.3. Number of Respondents Reporting Self-Management Behaviors and 

















Medical Formula      
Correctly reported medical formula 
prescriptiona 
4 6 9 9 0.21 
Formula preparation     0.01 
7 days per week independently — 4 5 6  
4-6 days per week independently 1 1 2 2  
≤3 days per week independently 7 4 1 1  
Someone else is responsible 3 — 2 —  
Do not drink formula — 1 1 2  
Dietary Phe/Protein Intake      
Correctly reported Phe/protein 
prescriptiona 
6 6 2 6 0.38 
Responsible for food records     0.006 
Always keep own food records — 2 — NA  
Keep own food records sometimes or 
assist parents 
5 7 4 NA  
Someone else is responsible  4 — — NA  
Do not keep food records 2 1 7 NA  
Tracks dietary Phe/protein intakeb NA NA 6 6 1.00 
Blood Phe Levels      
Correctly reported target blood Phe 
range 
3 4 7 9 0.06 
Collect blood Phe via finger stick     0.09 
Always collect sample independently 1 3 5 7  
Sometimes collect sample 
independently 
5 5 4 —  
Someone else is responsible 5 2 1 3  
Do not collect blood samples — — 1 1  
Note. NA, item not included in survey; Phe, phenylalanine 
 
a Participants able to report current prescription as listed in the medical record  
 
b Methods to track dietary Phe/protein intake include one or more of the following: 
keeping a written record or mental list of foods/protein consumed, limiting the 
variety of food consumed (protein content of common foods are often  




predominantly by limiting the variety of food consumed and/or keeping a mental list of 
Phe/protein consumed. 
Females 18-30 years of age (n=7) understood the influence of blood Phe levels on 
a developing fetus (maternal PKU) [39]. All participants correctly reported the target 
blood Phe range during pregnancy and most (n=5) reported blood Phe levels should 
ideally be within the therapeutic range 2-3 months prior to conception.  
2.4.2 Self-Management Behaviors, Treatment 
Knowledge, and Blood Phe Levels 
Correlations between individual questions and scales and presurvey Phe levels 
were assessed with Spearman rank-order correlation coefficients, considering survey 
data were ordinal. There were no significant associations between self-management 
measures and presurvey mean Phe or Phe variation (Table 2.4). The difference in pre-
survey mean Phe approached significance only for questions assessing dietary 
Phe/protein knowledge and monitoring (Table 2.5). 
Blood Phe levels and self-management were also compared by IEP eligibility. 
Presurvey mean Phe was not significantly different in participants with vs. without IEP 
eligibility (614±360 and 412±193 μmol/L, respectively, p=0.145). Nor was the combined 
self-management behavior and knowledge scale (1.8±1.7 and 3.4±1.2, respectively, 
p=0.054). 
As expected, knowledge of correct medical formula prescription, dietary 
Phe/protein prescription, and target blood Phe range were associated with significantly 
higher participation in their corresponding behaviors (p<0.005 for all). However, this 
association was not consistently significant for other behaviors (i.e., no significant 




Table 2.4. Univariate Spearman Rank Order Correlations between Presurvey Blood 


































































Note. Phe, phenylalanine 
a Phe variation measured as coefficient of variation (standard deviation/mean*100). 
For all correlations, the value of rho is shown followed by the 




Table 2.5. Comparison of Unadjusted Presurvey Mean Phenylalanine (Mean±SD) 
by Treatment Knowledge and Use of Dietary Phenylalanine 
Monitoring in Participants Aged 10–30 Years 
 
 Group  n 
Presurvey 
mean Phe  
 
p-valuea 
Knows correct medical formula prescription Yes 24 503±229 0.603 
 No 7 616±397  
Knows correct dietary Phe/protein prescription Yes 14 398±203 0.018 
 No 15 635±296  
Knows target blood Phe range Yes 20 520±231 0.934 
 No 11 544±345  
Uses method(s) to track dietary Phe/protein intake  Yes 12 527±193 0.055 
 No 9 704±220  
Note. Phe, phenylalanine 
 





Performing one self-management behavior was not consistently associated with 
participation in other self-management behaviors (Table 2.4). Participants who reported 
using one or more methods to track dietary Phe/protein intake were more likely to 
independently prepare medical formula (p=0.004) but not to collect blood samples 
(p=0.056).  
Self-management behavior and knowledge scales were negatively correlated with 
presurvey mean Phe levels (Fig. 2.3), though not reaching statistical significance. A 
potential confounder of this association was the number of blood samples, considering it 
is associated with self-management behaviors and impacts a 12-month average; 
therefore, we controlled for it in a multivariate linear regression. Age was not included in 
the model despite being a predictor of blood Phe concentrations [34, 40-42], as it is 
mostly related to behavioral factors as opposed to biological mechanisms. After 
controlling for number of blood samples, the combined behavior and knowledge scale 
model accounted for 24.9% of the variance in presurvey mean Phe, though increased 
self-management behaviors and treatment knowledge was not significantly associated 
with lower blood Phe levels (Beta=-95; p=0.024). 
2.5. Discussion and Conclusion 
2.5.1 Discussion 
Multiple studies have described poor treatment adherence in PKU and sequelae 
of elevated Phe concentrations [6-8, 40, 41, 43]. However, few have examined individual 
treatment knowledge and participation in self-management behaviors and how these 





Figure 2.3.  Spearman Rank-Order Correlations between Presurvey Mean 
Phenylalanine Concentrations and Scale Variables in Participants Aged 
10-30 Years. Three scale variables were created to capture self-
management behaviors (formula preparation and blood sample collection 
via finger stick) and treatment knowledge (knowledge of formula 
prescription, dietary phenylalanine/protein goal, and target blood Phe 




management skills in patients among three different age groups ranging from 7-30 years.  
Overall participation in self-management behaviors in our sample was lower than 
clinically recommended (Tables 2.1 and 2.3). Others have reported similar difficulties in 
adherence to treatment recommendations. In individuals with diabetes, only 54% of 
children and adolescents and 51% adults adhered to treatment guidelines [46, 47]. 
Additionally, an association has been reported between patient nonadherence and the 
complexity of specific therapies [15]. The treatment regimen for PKU is complex and 
must be followed day after day. Of 19 caregivers of a child with PKU, the majority 
reported difficulty adhering to recommended medical formula goals (53%) and dietary 
Phe/protein goals (84%) [45]. 
More 7-12 year olds in our sample engaged in age-appropriate management of 
dietary Phe/protein intake compared to older participants, whereas adolescents and adults 
demonstrated more self-sufficiency in formula preparation and blood sample collection 
(Table 2.3). Younger participants likely had increased parental assistance to monitor 
Phe/protein intake and provider emphasis on food records. Only 55% (n=12) of 
adolescent and adult participants regularly monitored dietary Phe intake, probably 
reflecting an increased social life and meals away from home. This result is comparable 
to a previous study reporting 45% of adolescents and adults with PKU correctly reported 
their dietary Phe/protein goal [44]. 
Treatment knowledge was related to increased participation in corresponding 
self-management behaviors in our sample. In contrast, another study found that an 
increase in knowledge did not lead to a concomitant increase in treatment adherence 




participants who, in order to manage their condition, were more likely to have 
knowledge of treatment goals. While knowledge alone may not be sufficient to initiate 
behavior, an understanding of the multifaceted treatment for PKU is necessary for 
appropriate management.  
Current evidence indicates adherence to one aspect of a treatment regimen does 
not imply adherence to all treatment components [8, 48]. We observed participation in 
selective self-management behaviors (Table 2.3) and an inconsistent association among 
self-management behaviors (Table 2.4). However, it is possible that certain behaviors are 
better indicators of overall self-management than others. In our sample, participants who 
reported using a method to monitor dietary Phe/protein intake, arguably the most time 
consuming treatment component, were significantly more likely to prepare formula 
independently (p=0.004). Therefore, those who monitor Phe/protein intake may be more 
likely to participate in other self-management behaviors. 
We anticipated participation in self-management behaviors and increased 
treatment knowledge to help achieve lower Phe levels. After controlling for number of 
blood samples, higher self-management skills and treatment knowledge were not 
significantly associated with lower mean blood Phe levels. However, the combined scale 
in this study did not include a measure of dietary Phe/protein monitoring, inclusion of 
which may have strengthened the model based on our univariate analysis. This is 
consistent with a previous report that increased difficulty with adherence to formula and 
dietary Phe/protein goals was associated with higher blood Phe levels (p=0.03 and 0.05, 
respectively) [45]. There was no association between self-management and variation in 




indicate participants’ consistency in following recommendations, thus informing our 
measure of blood Phe variation.  
There are several obstacles for the development of self-management skills in 
individuals with PKU. First, no mechanism exists to provide concurrent feedback on the 
influence of dietary Phe/protein consumption on blood Phe levels [49] or the effect of 
high blood Phe levels on long-term cognitive functioning [6]. A home blood Phe monitor 
capable of producing immediate results is not currently available, and many metabolic 
clinics receive blood Phe results 3-10 days after collection. Additionally, individuals may 
not experience or recognize symptoms of elevated Phe levels, which may reduce 
incentive to maintain Phe levels within the recommended range.  
External influences, such as clinic-guided dietary changes and parental control 
over food intake may reduce autonomy and motivation to engage in self-care [23, 50]. 
Parental knowledge of PKU dietary management also impacts blood Phe levels and 
likely self-management skills. Two studies described maternal knowledge of dietary 
treatment using the same questionnaire [51, 52]. Lower maternal knowledge of dietary 
Phe exchanges was correlated with higher blood Phe levels in children 1-15 years of age 
(p=0.043) [51] and lower overall dietary knowledge was associated with higher blood 
Phe levels in children 5-6 years of age (p<0.001) [52].  
Lastly, cognitive and/or executive impairments can inhibit development of self-
management skills [27, 28, 53]. Elevated blood Phe levels increase the risk for learning 
problems [54], which may then impair self-management abilities, though this was not 
demonstrated in our sample. One study reported lower measures of self-care in adults 




deficits [55]. This suggests individuals with PKU may require additional structure to 
achieve self-management goals, also demonstrated in this cohort with an increase in the 
number of blood samples with the use of a reminder strategy.  
Willingness and ability to engage in self-management behaviors is complex and 
influenced by a myriad of cognitive, psychological, and social factors. Strategies such as 
motivational interviewing, increasing personal agency, and action planning have also 
been used to enhance self-management in other chronic diseases with some success [23, 
56-58]. Future research is needed to evaluate these techniques to enhance engagement in 
self-management behaviors in patients with PKU. 
2.5.2 Limitations 
The results of this study should be interpreted in the context of its limitations. 
The self-management surveys were created by investigators and were not validated in a 
large sample, which is challenging considering the rarity of PKU. Rather, the surveys 
met content and cognitive standards and were piloted in a small patient sample. The 
study design introduced the potential for selection and self-report bias towards inclusion 
of patients who regularly attended clinic (the site of ascertainment); therefore, study 
participant characteristics may differ from those of patients lost to follow up or attending 
clinic infrequently. Additionally, all measures of self-management were based on 
participant-report. Participants may have over-reported participation in self-management 
behaviors based on social desirability, as suggested by previous studies reporting 
alterations in Phe/protein intake prior to blood draws in patients with PKU [8, 15]. 
During survey completion by participants, caregivers were requested to limit their 




creating the potential for caregivers influencing the participants’ answers. The 
generalizability of results is also limited to the extent that educational practices and 
clinical management at our clinic may differ from other clinics. Lastly, given our small 
sample size, we can only suggest associations and larger studies will be important to 
identify which factors are important.  
2.5.3 Conclusion 
Early and ongoing promotion of self-management skills is an important 
component of care for patients with PKU. Increased patient self-care has been linked to 
improved health outcomes in PKU and other chronic diseases. However, this was not 
demonstrated in our study, which may simply reflect small a sample size. Dietary 
Phe/protein knowledge and monitoring appeared to be the strongest individual factors 
associated with blood Phe levels and participation in other self-management behaviors; 
however, these factors did not increase from childhood to adulthood. Treatment 
knowledge may not be sufficient to influence behavior despite being critical to 
successful self-management. Overall, participation in self-management behaviors in this 
study was lower than is clinically recommended. More research is needed to determine 
the best methods to encourage patient self-management and to further explore the 
benefits of increased self-management in this population. 
2.5.4 Practice Implications 
We encourage use of the surveys presented in this study or a similar tool to 
facilitate discussions about age-specific self-management skills with patients and their 
families. Our clinic used the surveys in this manner in addition to evaluating current self-




waiting for providers. Providers reviewed the patients’ responses to survey questions 
during routine clinic appointments, which inherently created a structure in which to 
discuss the primary topics of self-management with each patient.  
The self-management measures most often associated with other positive 
behaviors were dietary Phe/protein intake knowledge and monitoring. This behavior was 
practiced in only about half of adolescent and adult participants. Tracking Phe/protein 
intake is tedious and may pose difficulties for individuals with learning impairments. 
This indicates a need for additional education and resources to facilitate dietary 
Phe/protein intake monitoring, especially considering its primary contribution to blood 
Phe concentrations.  
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PHONE-BASED MOTIVATIONAL INTERVIEWING TO 
 
INCREASE SELF-EFFICACY AND PATIENT 
 
ACTIVATION IN INDIVIDUALS WITH PKU2 
3.1 Abstract 
3.1.1 Objective 
To evaluate self-reported patient activation and self-efficacy in individuals with 
phenylketonuria (PKU) before and after a 6-month motivational interviewing (MI) 
intervention. 
3.1.2 Methods 
Participants (n=31) were 7-35 years of age and were divided into three age 
groups (preadolescents, adolescents, and adults). Participants completed online 
questionnaires assessing current stage of change (SOC), patient activation, and self-
efficacy. The intervention included monthly phone-based MI, goal setting, and a monthly 
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summary. Data were analyzed with descriptive statistics and mixed effects linear 
regression.  
3.1.3 Results 
Most participants were in the action/maintenance SOC for PKU treatment 
behaviors. Patient activation and self-efficacy were significantly different by age group 
(p<0.01 for both). Self-efficacy significantly increased from baseline to month 6 among 
adolescents and adults (7.4±1.9 and 8.6±1.3, respectively, p=0.002). There was no 
increase in patient activation (p=0.10).  
3.1.4 Conclusion 
The results of this study suggest phone-based MI is a potential method to increase 
self-efficacy for PKU self-management behaviors in adolescents and adults with PKU. 
3.1.5 Practice Implications 
MI is a potentially beneficial tool for metabolic clinics treating patients with PKU 
of a variety of ages. Additionally, pairing goal setting with MI may help reduce 
intellectual/executive barriers to implementing dietary treatments once the individual is 
motivated to take action. 
3.2 Introduction 
Poor treatment adherence has been described across a variety of behaviors and 
chronic diseases [1-4], including phenylketonuria (PKU) [5-7]. PKU is an inherited 
disorder of phenylalanine (Phe) metabolism causing intellectual/executive function 
deficits and behavioral disturbances [8-10]. PKU is typically diagnosed via newborn 




successful management of PKU involves daily monitoring of dietary Phe or protein 
intake, consumption of a Phe-free medical formula, weekly to monthly monitoring of 
blood Phe levels via finger stick, and regular food records and appointments with a 
metabolic clinic [11]. The treatment is designed to maintain blood Phe levels within a 
therapeutic range (120-360 μmol/L) [12], which improves cognitive and behavioral 
outcomes, quality of life, and reduces health care expenditures [13-17].  
Adherence to daily medical and/or dietary regimens is difficult to maintain, and 
becomes increasingly more difficult as treatment complexity increases [18, 19]. The 
ability to adhere to treatment recommendations in PKU may be further impaired by 
subtle cognitive deficits [10, 20]. In a study of 19 families with PKU, all children 
reported problems following the diet and 91% reported problems drinking medical 
formula primarily due to issues with the daily regimen, lack of treatment knowledge, 
palatability, and social aspects of the diet. Many of the strategies for dealing with 
problems related to protein intake (73% of strategies) and formula intake (43% of 
strategies) were maladaptive and were correlated with elevated blood Phe levels [21].  
Individuals are also faced with different adherence challenges at different ages. A 
qualitative study of 37 individuals with PKU aged 8-31 years reported age-related 
themes regarding their perception of having PKU. The preadolescents were gaining more 
awareness of PKU and learning to deal with peer confrontation; adolescents were 
acquiring self-management responsibilities and dealing with shifting relationship with 
parents; and young adults were developing autonomy and self-reference and later 
focusing on how PKU affects jobs, relationships, and future children [22]. Perhaps partly 




with age [5, 6, 8, 9, 23] with approximately 20% of adolescents and adults with PKU 
maintaining blood Phe levels within the therapeutic range [8]. 
Strategies to facilitate behavior change are needed to address the challenges with 
treatment adherence in individuals with PKU and other chronic diseases. Two potential 
mediators of behavior change include patient activation and/or self-efficacy. Increased 
patient activation and self-efficacy have been repeatedly associated with improved self-
management behaviors, health outcomes, and reduced health care costs among 
individuals with a variety of chronic diseases [19, 24-31], suggesting practitioners should 
foster these attributes in their patients.  
Patient activation has become a topic of interest in recent years. An activated 
patient has the knowledge, skills, confidence, and motivation to manage his/her own 
health. High activation was associated with increased self-management in 479 adults 
with hypertension, diabetes, and arthritis [28]. Similar to stages of change (SOC), patient 
activation occurs on a continuum of four levels with individuals theoretically proceeding 
through each level to become effective self-managers. However, patient activation 
differs from SOC in that it is not specific to one behavior and it encompasses knowledge 
and skills, which are not directly addressed in SOC [32].  
Self-efficacy is defined as the belief that one can successfully implement a 
behavior required to achieve the desired outcome [33]. Meta-analyses have reported 
positive associations between self-efficacy and participation in recommended self-care in 
adults with type 1 and 2 diabetes and adherence to antiretroviral therapy in individuals 
with HIV [19, 31]. In a cohort of 357 adolescent females, goals to make healthy food 




(p<0.01) [30]. Increased parental self-efficacy regarding medical formula intake 
(p=0.007) and raising a child with PKU (p=0.028) was also associated with improved 
blood Phe levels in children with PKU [34]. 
Tailored interventions based on an individual’s self-reported SOC or patient 
activation have been shown to be more effective in improving activation, self-efficacy, 
and health behavior change compared to more traditional approaches [26, 35-38]. 
Motivational interviewing (MI) is commonly used in conjunction with SOC to provide 
tailored counseling based on one’s readiness to change. MI is a patient-centered, 
collaborative style of communication designed to elicit intrinsic motivation for change. 
MI explores ambivalence while supporting patient autonomy in order to reduce 
resistance and elicit change talk from the patient [39-43].  
There are multiple studies and meta-analyses supporting the effectiveness of MI 
to improve self-efficacy, self-management behaviors, and health outcomes when 
compared to controls (no treatment, standard of care, or information only) [44-49]. One 
meta-analysis reported improved self-efficacy with MI interventions in patients with 
diabetes, cardiovascular disease, or smoking, producing an overall effect size of 1.39 
(95% CI 1.09-1.78, n=7 studies) [47]. Other improvements have been found in self-
monitoring (blood sugar, food intake, and exercise), glycemic control, blood pressure, 
cholesterol, HIV viral load, and body weight [47, 50, 51]. MI has also demonstrated 
positive results in a variety of settings, such as phone-based MI [44, 52-54], and age 
groups, including children and parents, adolescents, and adults [48, 49, 55, 56].  
We hypothesize the use of phone-based MI in conjunction with monthly goal 




Patients with PKU may benefit from more dynamic interaction with providers, as this 
genetic disease requires lifelong treatment. The current study evaluated self-reported 
SOC, patient activation and self-efficacy before and after a 6-month intervention 
comprised of monthly phone-based MI delivered by a metabolic dietitian, goal setting, 
and a monthly summary.  
3.3 Methods 
3.3.1 Participants 
Study participants were individuals aged 7-35 years, diagnosed with PKU on 
newborn screening and treated within 1 month of birth. All participants were English 
speaking and had Internet access at home. Exclusion criteria included 1) intellectual 
disability (ID, IQ<70), 2) pregnancy, as excess Phe is teratogenic and requires different 
treatment guidelines [12], 3) hyperphenylalanemia not requiring dietary treatment, and 4) 
concurrent participation in clinical trial(s) testing enzyme substitution therapy. Patients 
were identified and recruited through the Utah Metabolic Clinic from December 2013 to 
July 2014. Participants were compensated monetarily for their time. The University of 
Utah Institutional Review Board approved this study and written consent – and child 
assent, if appropriate – was obtained for all participants. 
3.3.2 Measures 
3.3.2.1 Stages of Change  
The research team compiled a questionnaire to assess participants’ current SOC 
based on the format of previous questionnaires shown to be reliable [57, 58] (Appendix 
B). Treatment of PKU is complex and multiple behaviors contribute to blood Phe levels 




dietary Phe/protein goals, meeting medical formula goals, and making healthy food 
choices. Healthy food choices do not affect Phe levels to the same extent as Phe/protein 
and medical formula goals. However, inclusion of this domain provided an opportunity 
to discuss other areas of improvement for those already meeting Phe/protein and formula 
goals and to provide options for those who may not be ready to discuss working towards 
Phe/protein or formula goals. Participants were asked to select the most important 
behavior from a list within each behavioral domain (Table 3.1). If none of the items 
pertained to the participant, he/she could write in another behavior of interest. For each 
domain, the SOC was scored on a progressive scale that ranged from “1” (absence of the 
desire to change behavior) to “5” (presence of the desire to maintain a changed 
behavior). The corresponding numbers to the participant’s SOC are as follows: 
precontemplation=1, contemplation=2, preparation=3, action=4, and maintenance=5.  
3.3.2.2 Patient Activation 
Activation was measured with the abbreviated Patient Activation Measure (PAM-
13). This questionnaire measures perceived knowledge, ability, and confidence to 
manage one’s health [32]. PAM-13 scores range from 0 to 100, and this score can then 
be divided into four levels of activation [60]. The levels reflect a patient’s belief that 
he/she should play an active role in self-care and collaborate with providers (level 1), 
knowledge about one’s disease and its treatment (level 2), confidence to support new 
behaviors (level 3), and ability to maintain lifestyle changes in times of stress (level 4) 
[32]. The PAM-13 was validated in a cohort of adults (n=1515) and has not been 
validated in children [32]. Patient activation was included in this study considering it 




Table 3.1. List of Behavioral Targets for Stage of Change Questionnaire 
Domain List of behaviors 
  
Dietary Phe/protein  Count how much Phe/protein I eat  
Keep diet records  
Plan meals beforehand  
Watch my portion sizes 
Prepare meals at home 
  
Medical formula  Drink all formula every day  
Drink formula several times per day  
Make my own formula  
Bring my formula to school/work  
Try a different formula or try to improve the 
taste of my current formula 
  
Healthy food choices Eat more fruits/vegetables  
Drink fewer sweetened drinks (soda, juice)  
Eat out less often (restaurants, fast food)  
Eat fewer "junk foods" (chips, cookies, candy)  
Cook meals at home more often 
  
Note. Phe, phenylalanine. Participants were asked to “Choose the single 
most important thing you could personally do to meet your 




successful PKU management. Also unlike the SOC and self-efficacy questionnaires, it is 
not behavior specific, allowing a more general measure of activation for self-care. 
3.3.2.3 Self-Efficacy  
Self-efficacy was measured with a modified version of the 8-item Diabetes Self-
Efficacy Scale developed at the Stanford Patient Education Research Center [61, 62]. 
Items were ranked on a 10-point Likert scale ranging from 1 (not confident) to 10 (totally 
confident). The total score reflected the average of the eight items rather than the sum to 
maintain the original metric. The wording of items 2, 5, 6, and 8 was revised to apply to 
someone with PKU (e.g., substituting “blood sugar” with “phenylalanine”). The topic of 
items 1 and 4 was replaced with statements regarding the ability to consume medical 
formula and collect blood samples, as the original topics (frequent meals and exercise) 
were not meaningful to the management of PKU (Appendix C).  
3.3.2.4 Blood Phenylalanine 
Participants collected a blood Phe sample via finger stick at baseline and were 
asked to collect monthly blood samples as part of standard of care monitoring during the 
study.  
3.3.3 Interventions 
3.3.3.1 Monthly Summary 
A monthly PDF was emailed to participants to summarize previous responses 
(Appendix D). It displayed each participant’s current SOC for selected behaviors within 
the three domains, monthly goal, prescribed protein intake, and average protein intake 




Participants received the summary prior to phone-based MI with instructions to review 
the information prior to the call, though they were not required to view the summary 
during the conversation.  
3.3.3.2 Phone-Based Motivational Interviewing 
Participants were contacted by phone once per month during the 6-month 
intervention. Author Krista Viau delivered the MI intervention. The interventionist 
received more than 30 hours of MI training via workshops, individual coaching and 
expert practice feedback. The sessions were audio recorded and a random sample was 
reviewed by author Michael Adelman, who was also trained in MI, to evaluate reliability 
of the MI intervention and give practice feedback. Calls were made after metabolic clinic 
staff received monthly blood Phe results, generally 5-10 days after sample collection. For 
participants less than 18 years of age, telephone counseling was conducted with either 
(1) the caregiver and participant concurrently or (2) participant alone followed by a 
verbal summary provided to the caregiver.  
The interventionist reviewed topics on the summary and the participant’s blood 
Phe result at the beginning of the session. After the initial discussion, participants were 
asked if he/she would like to focus on anything in particular the following month. A list 
of options was presented if the participant did not have a particular topic in mind. MI 
techniques aimed to understand the participant’s goals and values, barriers to change, 
and elicit personal motivation for change were used during the session to explore 




3.3.3.3 Monthly Goals 
Topics for monthly goals were derived from the discussion, particularly 
participant change talk. While current SOC for behavioral domains were discussed 
during the phone conversation, the participant had the option of choosing a goal that was 
separate from the behaviors selected on the SOC questionnaire. Each month participants 
were asked if they would like to form a goal, though they were reminded they could 
choose to maintain current health if they did not identify a specific change they were 
ready to implement. If the participant was interested in creating a goal, the interventionist 
assisted to design goals that were specific and measureable according to guidelines [64]. 
The interventionist reviewed the participant-reported progress of the previous month’s 
goal, and discussed next steps during the following month’s telephone conversation.  
3.3.4 Data Collection 
Study data were collected and managed using the REDCap electronic data 
capture tools hosted at University of Utah [65]. Participants were instructed on 
questionnaire completion during the in-person baseline visit. All questionnaires were 
emailed to participants and completed online using REDCap survey tools. Participants 
under 18 years of age were asked to complete the questionnaires with a caregiver. Krista 
Viau clarified individual responses with participants over the phone as needed. The SOC 
and food frequency questionnaires were administered monthly. Patient activation and 
self-efficacy questionnaires were completed at baseline and months 3 and 6. Participants 
were asked to collect blood samples the same day as questionnaire completion.  
Demographic and treatment information including date of birth, sex, current 




prior to enrollment, and eligibility for an individualized education program (IEP) were 
obtained from the electronic medical record. IEP eligibility was used as a proxy for the 
presence of learning problems. Adult participants were classified based on previous IEP 
eligibility.  
3.3.5 Data Analysis 
Demographic, questionnaire and monthly goal data were summarized using 
descriptive statistics: continuous variables were reported as mean ± standard deviation if 
normally distributed and median (interquartile range (IQR)) if not normally distributed, 
and categorical variables were reported as frequencies. Differences between data at 
baseline were assessed via Fisher’s exact test for categorical data and one-way ANOVA 
for continuous data. Correlation between total goals created and total goals achieved was 
assessed with Spearman correlation coefficients due to the small sample size.  
Due to repeated measurements in each participant, we used random effects linear 
regression to evaluate differences between IEP eligibility, age categories, and number of 
goals created and achieved. Random effects linear regression was also used to compare 
baseline patient activation and self-efficacy to month 3 and month 6 scores, controlling 
for potential confounders. We used an intention-to-treat analysis. Statistical analyses 
were performed using Stata 13.0 (StataCorp, College Station, TX). Significance was 
defined as a two-sided p-value with alpha of 0.05.  
3.4 Results 
Forty-six percent of patients invited to participate enrolled in the study (Fig. 3.1). 
Participants fell into three age categories, preadolescents (7-12 years), adolescents (13-







Figure 3.1.  Flow Chart of Participant Recruitment, Enrollment, and Retention. Patients in the metabolic clinic database include 
all known patients in Utah who have been seen in our clinic and a portion of patients from surrounding states,  
including Idaho and Wyoming. 
 
Eligible patients invited to 
participate (n=68) 
Initial eligibility identification 
(n=93) 
Patients with PKU in the 
metabolic clinic patient database 
(n=183) 
Declined (n=37) 
∙ Time requirements (n=2) 
∙ Travel for baseline visit 
(n=2) 
∙ Health/family concerns (n=2) 
∙ Blood samples (n=1) 
∙ No response (n=14) 
∙ No reason provided (n=16) 
Excluded (n=89) 
∙ Moved (n=26) 
∙ Age criteria (n=24) 
∙ Intellectual disability (n=17) 
∙ Spanish speaking (n=1)  
∙ Hyperphenylalaninemia 
(n=5) 
∙ Concurrent participation in 
clinical trial(s) (n=16)  
Excluded (n=26) 
∙ Lost to follow up for >36 
months  
Completed month 6  
(n=26) 
Attrition (n=5) 
∙ Discontinued after month 1 
due to time requirements 
(n=1) 
∙ Lost to follow up after month 
2 (n=1) and 5 (n=2) 
∙ Pregnancy at month 2, 
remainder of data censored 
(n=1) 





Table 3.2. Demographic and Baseline Treatment Information for Participants with PKU, 






(7-12 yrs)  
n=11 
Adolescent 
(13-17 yrs)  
n=5 
Adult 





      




















Female 22 8 1 13 0.032 
Overweight/Obese 16 2 3 11 0.016 
IEPa 7 2 1 4 1.00 
Taking Medical 
Foodb 
28 10 5 13 1.00 
BH4 Treatment 14 8 1 5 0.09 
      
Note. BH4, tetrahydrobiopterin; IEP, individualized education program; IQR, 
interquartile range; Phe, phenylalanine 
 
a Participants currently or previously eligible for an IEP in school as an indicator of 
learning impairment.  
 
b Participants reporting regular medical food intake at enrollment. 
 
c Differences between groups assessed with Fisher’s exact test for categorical data and 




participants’ blood Phe concentrations were above the therapeutic range at baseline (120-
360 μmol/L) [12], which was significantly different between the age categories 
(p=0.036). Participants completed a median of five (4-6) of the 6 monthly phone-based 
MI sessions with the median duration of 13 minutes (10.5-16). Thirty-one participants 
completed baseline questionnaires, 28 completed month 3 questionnaires, and 26 
completed month 6 questionnaires. 
3.4.1 Stages of Change 
At baseline, most participants reported being in action or maintenance stages 
(Table 3.3). There was no significant difference in baseline SOC between age categories 
for any domain (data not shown). No participants were precontemplative for all three 
behavioral domains. The majority of participants’ SOC remained stable throughout the 
intervention. SOC related to Phe/protein goals increased over the intervention for 7 
participants and decreased for 5 participants; medical formula goals increased for 4 
participants and decreased for 2 demonstrated participants; and healthy choices increased 
in 6 participants and decreased for 3 participants. All participants who decreased their 
SOC at month 6 were in the action or maintenance stages at baseline and 3/7 had 
selected a different behavior at month 6 compared to baseline. 
Participants indicated their current SOC for one behavior per month within each 
domain. Most chose different behaviors throughout the intervention (n=20 for 
Phe/protein goals, n=13 for formula goals, and n=20 for healthy choices). The number of 
different behaviors selected for the three behavioral domains were not significantly 
associated with the SOC for that domain. Hypothesis testing was not performed for 














    
Precontemplation 1 — — 
Contemplation 6 — 5 
Preparation 5 5 5 
Action 5 6 10 
Maintenance 14 20 11 
    
Note. Baseline stage of change reflects the behavior with 




3.4.2 Monthly Goals 
Participants created a total of 118 goals during 150 cumulative counseling 
sessions. Goals varied throughout the intervention with a median of three (2-4) distinct 
goals per participant. Of these, 58.4% of goals were achieved per participant report. The 
number of different goals was not correlated with the percentage of goals achieved 
(p=0.80). Monthly goals were not always consistent with the behaviors selected on the 
SOC questionnaire. Nearly one-third (31.4%) of participant goals were focused on 
Phe/protein intake, 22% medical formula intake, 5.1% regular BH4 intake, 21.2% 
healthy choices, 17.8% exercise, and 2.5% nonhealth related topics. The total number of 
goals created and the number of goals achieved during the intervention were not 
significantly different by IEP eligibility (p=0.36 and p=0.59, respectively) and were not 
associated with baseline stage of change, patient activation, or self-efficacy scores (data 
not shown).  
3.4.3 Patient Activation and Self-Efficacy 
At baseline, most participants had patient activation scores reflecting high 
activation levels 3 and 4; Fig. 3.2), and had moderate self-efficacy scores (Table 3.4 
Participants completing the intervention and those who discontinued prior to 6 months 
(Fig. 3.1) had similar median patient activation scores (71 (53-78) and 69 (50-73), 
p=0.94) and self-efficacy scores (7.9 (5.4-8.8) and 7.3 (5.1-8.8), p=0.64) at baseline. 
Over the course of the study, 4 participants maintained their baseline activation scores, 
15 participants increased activation scores, and 4 participants decreased activation 
scores. Total self-efficacy scores increased for 19 participants during the intervention 














Figure 3.2.  Patient Activation Levels for Participants at Baseline, Month 3, and 
Month 6 (n=25). Excludes participants with missing patient activation 
scores at month 3 or 6 (n=6). Level 1 reflects a belief that taking an active 
role is important; level 2 reflects confidence and knowledge to take 
action; level 3 reflects taking action; and level 4 reflects the ability to 
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Table 3.4. Individual Self-Efficacy Scores by Question for Participants with 













     
You can do all the things necessary to 
manage your PKU on a regular basis. 
7.0±2.2 7.5±2.1 8.0±2.3 +1.0 
     
You can follow your diet when you 
have to prepare or share food with 
other people who do not have PKU. 
7.5±2.5 7.5±2.0 8.5±1.4 +1.0 
     
You can choose the appropriate foods 
to eat when you are hungry (for 
example, snacks). 
7.5±2.4 7.9±1.4 7.9±1.8 +0.4 
     
You can poke your finger to collect a 
blood sample every month at a 
minimum. 
7.7±2.9 8.0±2.8 7.8±2.7 +0.1 
     
You can do something to prevent your 
blood phenylalanine levels from 
increasing. 
6.7±2.4 7.1±2.4 7.5±2.5 +0.7 
     
You know what to do when you blood 
phenylalanine level goes lower or 
higher than it should be. 
7.1±2.8 6.9±2.4 7.7±2.6 +0.6 
     
You can judge when changes in your 
illness mean you should visit the 
doctor. 
6.3±2.7 6.3±2.8 7.1±2.7 +0.8 
     
You can control your PKU so that it 
does not interfere with the things you 
want to do. 
7.9±2.3 8.0±1.7 8.6±1.6 +0.7 
     
Note. 1=not confident and 10=totally confident. Questions from modified version of the 




Self-management responsibilities increase with age [66] and a concomitant 
increase in activation and self-efficacy are expected. In our participants, patient 
activation and self-efficacy scores were significantly different between age categories 
(p<0.01 for both). The mean activation score was 61.4±18.5 for preadolescents, 
70.5±18.9 for adolescents, and 74.5±14.6 for adults. The mean self-efficacy score was 
6.7±1.7 for preadolescents, 7.7±1.5 for adolescents, and 8.1±1.7 for adults. 
The change in patient activation and self-efficacy was assessed with random 
effects linear regression. IEP eligibility was not included in the model, as it was not 
significantly associated with patient activation or self-efficacy in bivariate regression 
models (p=0.83 and 0.33, respectively). Considering the difference in mean activation 
and self-efficacy between age groups, we stratified the analysis by age category. 
However, adolescents and adults were combined into a single category, as there were 
only 5 participants in the adolescent category. After controlling for age, patient 
activation did not significantly change over the course of the intervention (β=5.1, 
p=0.10; Fig. 3.3A). This was consistent with results after stratifying by age group 
(p=0.19 for preadolescents and p=0.24 for adolescents/adults). However, self-efficacy 
scores significantly increased from baseline to month 6 (β=0.68, p=0.017; Fig. 3.3B). 
After stratifying by age group, the adolescent and adult age group demonstrated a 
significant increase in self-efficacy from baseline to month 6 (β=1.06, p=0.002), though 
this was not found in the preadolescent age group (β=0.13, p=0.79). 
3.5 Discussion and Conclusion 
To our knowledge this is the first study to use motivational interviewing and goal 





Figure 3.3.  Predicted Means ± Standard Error for Patient Activation (A) and Self-
Efficacy (B) for All Participants from Baseline to Month 3 and Month 6. 
Random effects linear regression used to estimate slope in patients with 
PKU. Patient activation was scored from 0-100 and self-efficacy was 
scored from 1-10; with both measures, higher scores reflected increased 




with PKU. Patients’ knowledge and engagement in their own care are crucial for chronic 
disease management. The treatment for PKU is complex, and many with PKU have 
subtle intellectual and/or executive deficits; therefore interventions that increase 
motivation and confidence in managing one’s health are ideal for individuals with PKU. 
Our primary finding was a significant increase in self-efficacy to manage a variety of 
behaviors involved in the treatment of PKU after the 6-month MI intervention. 
MI has demonstrated positive outcomes with a variety of age groups [47-49]. Our 
sample included participants aged 7-35 years. While it is crucial to engage younger 
patients in their care and provide opportunity for skills mastery [59, 67, 68], we noted 
differences in the efficacy of MI in the youngest participants compared to adult 
participants. This may be explained by their developmental stage, which often includes a 
lesser understanding of illness-related concepts, expressive language skills, and ability 
tolink current behavior with past events or long-term goals when compared to 
adolescents and adults [69]. Therefore, programs targeting preadolescents would likely 
be most effective when involving both parents and children in the MI intervention [48]. 
In contrast, MI is well suited for adolescence considering this period is typically 
characterized by ambivalence, desire for autonomy, and development of self-identity 
[69-71]. Despite age-related challenges, including younger participants is important to 
increase self-management behaviors and reduce the likelihood of poor treatment 
adherence later in life. 
We assessed each participant’s current SOC prior to the monthly MI intervention. 
This provided context regarding the participant’s current readiness to take action and 




in action/maintenance stages for medical formula goals (Table 3.2). This indicates our 
population adhered to formula recommendations more often than other behavioral 
domains, which is also consistent with our clinical experience.  
Most participants changed their selected SOC behaviors over the 6-month period 
(Table 3.1), which demonstrates the flexibility of the intervention. The exploratory 
nature of MI may encourage participants to select a behavior they had not considered 
previously. While flexibility is important in MI, this design limited our ability to follow 
up on the change in SOC for each behavior. Therefore, we were unable to determine if a 
change in SOC behaviors reflected a lack of readiness for the behavior change or 
successful implementation of the behavior. Future studies might collect SOC for a 
variety of specified self-management behaviors in order to determine if MI facilitates 
increasing readiness to change over time.  
The majority of participants had high activation scores throughout the 
intervention (Fig. 3.2). PAM scores did not significantly increase from baseline to month 
6 (Fig. 3.3A). PAM-13 was validated in adults and our sample had a large percentage of 
participants in the preadolescent (35%) and adolescent (16%) age groups. While we do 
not expect a preadolescent or even adolescent population to agree with some of the 
PAM-13 statements (e.g., “When all is said and done, I am the person who is responsible 
for taking care of my health”) [32], there was also no significant change in activation 
scores for participating adults (p=0.32). This suggests the 6-month MI intervention did 
not have a significant impact on overall patient activation in this sample and/or that the 
PAM-13 may not be the appropriate tool for this population to reflect a difference in 




Self-efficacy for tasks relating to PKU management significantly increased over 
the 6-month MI intervention (Fig. 3.3B). However, the change was not significant at 
month 3, indicating change in self-efficacy may take time to develop. The significant 
change in self-efficacy was only found for adolescent and adult participants’ self-
efficacy and not for preadolescents. This may be related to the expected self-
management skills at varying ages. Adolescents and adults have greater self-management 
responsibilities compared to younger participants; therefore, confidence regarding 
specific skills related to PKU management may have a greater potential to increase in 
older participants.  
It is possible that the increase in participant-reported self-efficacy reflected 
regression to the mean, in which repeated measurements are less extreme than the first 
measurement. In our sample, 5 participants had baseline self-efficacy scores in the lower 
half of the range (score ≤5) and were mostly preadolescents (n=4). However, there was 
no significant increase in self-efficacy in the preadolescent group, suggesting regression 
to the mean was not the underlying cause of reportedly increased self-efficacy. The best 
method to account for potential regression to the mean is inclusion of a randomized 
control group [72]. 
Previous research has shown a positive association between self-efficacy and 
participation in action planning and self-monitoring in adults [73, 74]. We were unable to 
determine if the increase in self-efficacy in our population was due to a specific 
component of the intervention (MI, goal setting, monthly summary) or the intervention 
as a whole. However, our results did not show an association between goal setting and 




engaging in recommended behaviors, and thus chose to maintain current health rather 
than create a monthly goal.  
For most participants, outcome measures increased over the course of the 
intervention. However, SOC, activation, and self-efficacy decreased for a few 
participants. For SOC, we are unable to compare baseline to month 6 as participants 
selected different behaviors. Reported decreases in patient activation or self-management 
may reflect questionnaire fatigue and/or regression to the mean. Additionally, several of 
these participants cited life stressors impairing their ability to adhere to treatment 
recommendations during the intervention, though they completed the intervention. We 
were unable to compare this to participants who discontinued the study, though baseline 
data were similar. Many patients, particularly adults, are lost to follow up with an 
estimated 77% of adults with PKU were not followed by a metabolic clinic in 2012 [75]. 
Maintaining patient rapport and engagement is a fundamental part of the treatment plan. 
Use of MI may help achieve these goals and subsequently increase the likelihood of 
patients continuing with treatment into adulthood [76].  
Subtle intellectual and/or executive deficits may impair one’s ability to manage 
the complex treatment for PKU. Studies in other populations have reported a negative 
association with executive functioning and self-management and/or treatment adherence 
[77, 78]. In contrast, our results did not show a significant difference in number of goals 
created or achieved, patient activation, or self-efficacy scores between individuals with 
or without learning problems. While many individuals with PKU have subtle 
cognitive/executive deficits, we suggest MI remains a potentially beneficial tool. MI 




80], which has increased rates of mental illness and executive deficits [81], and has been 
successfully used to increase engagement in patients with a traumatic brain injury [82]. 
Although the current study excluded individuals with ID, these findings support further 
exploration of MI as a potential intervention to facilitate treatment adherence in 
individuals with PKU and more severe intellectual deficits.  
3.5.2 Limitations  
The design of this study introduced potential for selection and self-report bias. 
Many adults with PKU were lost to follow up in our clinic and may have different 
characteristics than patients currently attending a metabolic clinic. Additionally, those 
that declined participation may have lower baseline SOC compared to participants. Self-
reported data may also be overestimated, also suggested in a recent meta-analysis of MI 
interventions showing self-reported outcomes had greater effect sizes compared to 
objective outcomes [47]. Additionally, rather than a separate control group, participants 
acted as their own control, which addressed participant matching but failed to control for 
a potential Hawthorne effect. The reliability of the MI intervention was evaluated and 
practice feedback provided. However, the intervention was delivered by one dietitian, 
and needs to be replicated with other interventionists to evaluate its reliability and 
generalizability. The questionnaires used in these studies were modified and/or used in 
populations not meeting the age criteria in the original validation studies, which 
increased the risk of systematic bias. Additionally, learning impairment was measured 
with IEP eligibility, which may not include all participants needing an IEP and, 
conversely, potentially include participants with an IEP for less substantial learning 




small, reducing power. The study included preadolescent, adolescent, and adult 
participants to increase the study population. However, these factors limit our ability to 
determine the efficacy of this intervention. Studies with larger sample sizes in each age 
group are needed to understand the impact of phone-based MI on patient activation and 
self-efficacy.  
3.5.3 Conclusion 
The 6-month phone-based MI intervention, in conjunction with goal setting and a 
monthly summary, was associated with a significant increase in self-efficacy for PKU 
self-management behaviors among adolescent and adult participants. Our results indicate 
patient self-efficacy takes time to develop, as there was no significant difference in self-
efficacy after 3 months. This association was not found for patient activation. Measures 
of SOC identified that the majority of participants were currently performing or 
maintaining self-care behaviors. The results of this study suggest phone-based MI is a 
potential method to increase self-efficacy in adolescents and adults with PKU. 
Additional research is needed to further evaluate the efficacy of MI in a larger cohort of 
patients with PKU and with different age groups. 
3.5.4 Practice Implications 
Results from this study suggest MI is an appropriate tool to enhance self-efficacy 
for PKU self-management behaviors. Self-efficacy may increase the likelihood of 
treatment adherence in patients with PKU, as has been reported in other chronic diseases. 
Additionally, pairing goal setting and action planning with MI may help patients 
construct an individualized and feasible plan once they are prepared to take action. While 




mastery experiences [73].  
MI may be beneficial with patients of a variety of ages, though developmental 
stage and differing stressors related to PKU management need to be considered. We 
recommend using an MI intervention with both parents and children or preadolescents 
with PKU to facilitate confidence and behavior change, considering self-management 
responsibilities begin early in chronic disease. Adolescents may respond to the autonomy 
support emphasized in MI. Additionally, MI may be a beneficial addition to initiatives 
aiming to engage adult patients lost to follow up in a metabolic clinic [75]. The patient-
centered nature of MI has potential to maintain patient rapport and keep patients engaged 
in a metabolic clinic. 
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A NOVEL APPLICATION OF MOTIVATIONAL 
 
INTERVIEWING TO IMPROVE TREATMENT 
 
ADHERENCE IN PHENYLKETONURIA3 
4.1 Abstract 
4.1.1 Objective 
The objective of this study was to demonstrate the efficacy of a 6-month phone-
based motivational interviewing (MI) intervention to reduce blood phenylalanine (Phe) 
slope and improve diet adherence in individuals with phenylketonuria (PKU) using a 
before-and-after design. 
4.1.2 Methods 
Participants (n=31) were 7-35 years of age and completed stage of change (SOC), 
self-efficacy, and food frequency questionnaires online. Pre-intervention blood Phe 
levels collected within 6 months of enrollment were compared to blood Phe during the 
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intervention. The intervention included monthly phone-based MI, goal setting, and a 
monthly summary. Data were analyzed with descriptive statistics, Fisher’s exact test, 
Mann-Whitney U test, and mixed effects linear regression.  
4.1.3 Results 
There was no significant change in dietary adherence over the intervention, 
though the majority of participants (n=28/31) reported adherence to medical formula at 
baseline. After controlling for baseline SOC and learning problems, the pre-intervention 
blood Phe slope for all participants (β=0.71) was not significantly different from the 
intervention slope (β=0.26, p=0.13) and not different based on age (p=0.77). Higher SOC 
at baseline (β=-61.6, p=0.005) and self-efficacy (β=-64.5, p<0.001) were associated with 
a decrease in blood Phe slope. 
4.1.4 Conclusion 
This study suggests MI is feasible in a PKU population and lends support to the 
link between SOC, self-efficacy, and behavior change. SOC and self-efficacy may be 
future targets for behavioral interventions to improve metabolic control in patients with 
PKU. However, a larger sample size and longer follow-up are needed to further explore 
potential benefits of MI in this population. 
4.2 Introduction  
Phenylketonuria (PKU) is a challenging chronic disease to manage, requiring 
patients and families to perform multiple, interrelated tasks on a daily basis. Hence, there 
are several barriers to optimal and lifelong treatment, such as habitual consumption of 




keeping frequent food records and obtaining blood samples [1, 2]. Recently, there have 
been improvements in availability and taste of protein foods and medical formulas as 
well as new treatment options [2, 3]. However, for many individuals with PKU, the diet 
remains highly restrictive. Therefore, it is not surprising that treatment adherence 
declines with age, resulting in increased blood Phe concentrations [4]. Sequelae of 
elevated blood Phe levels, such as learning problems and reduced achievement, slowed 
processing speed, increased executive functioning deficits, increased anxiety and 
emotional disorders develop as many adolescents and young adults liberalize or abandon 
dietary Phe restriction [4-10]. 
There are a myriad of factors influencing one’s ability to adhere to treatment 
guidelines and manage their own care [2, 11, 12]. Self-efficacy, problem solving and 
coping skills are required to deal with the physical, social, and psychological 
consequences of a chronic illness [12-14]. In PKU, deficiencies in self-management 
skills contribute to poor treatment adherence and detrimental cognitive and 
neuropsychological outcomes [15-17].  
Poor treatment adherence is not specific to individuals with PKU; rather it is a 
prevalent phenomenon among individuals experiencing chronic illness [18-21]. 
Increased self-management and treatment adherence are associated with improved health 
outcomes and reduced health care expenditures [22-25]. Despite these benefits, it is a 
common finding that prescriptions are not filled, healthy lifestyle choices are not 
implemented, and/or self-management behaviors are lacking [21, 26-29]. The 
discrepancy between potential health benefits and actual behavior change may be due, in 




both arguments for and against change [30]. Traditionally, our health care system 
responds to ambivalence with direct questioning, giving advice, and attempting to 
convince patients to change their behaviors [31, 32]. These strategies often lead to 
increased resistance to change and leave both practitioners and patients frustrated [33, 
34].  
Motivational interviewing (MI) is a patient-centered, directive counseling style 
that explores ambivalence to elicit intrinsic motivation for behavior change [30]. The 
foundation of MI is an atmosphere of collaboration, compassion, evocation, and 
acceptance. MI employs strategies, such as reflective listening, supporting patient 
autonomy to decide whether or not to change, and reducing resistance. Whereas in the 
traditional model direct questioning and giving advice are normative, MI suggests 
collaboration among experts, where the provider is the expert on the condition/treatment 
and the patient is the expert on himself or herself [30]. This structure allows practitioners 
to elicit and reinforce change talk, in which the patient states reasons for change. The 
practitioner guides the patient and helps them identify discrepancies between their 
current actions and their desired outcomes, creating opportunity for the patient to 
develop motivation to change.  
Meta-analyses consistently demonstrate a modest, positive association between 
MI and health outcomes despite differences in targeted health behaviors, delivery 
settings, and provider type [35-38]. In medical settings, participants receiving MI were 
1.55 times more likely to have positive outcomes compared to controls [35]. A similar 
result was noted in pediatric populations (effect size: 0.28 (95% CI 0.24-0.32)) with 95% 




effectively as the sole intervention, in combination with other programs, and as a method 
to increase engagement in other programs, such as educational programs or cognitive 
behavioral therapy [37, 39].  
Intermediate outcomes, such as self-efficacy and progressing through stages of 
change (SOC), are common targets of behavior change interventions, as they are 
theorized precursors to actual behavior change [40]. Self-efficacy reflects confidence to 
successfully engage in a behavior, and SOC reflects one’s readiness to engage in a 
behavior, ranging from precontemplation to maintenance [40]. Meta-analyses have 
shown an association between MI and self-efficacy [35], as well as between self-efficacy 
and self-management behaviors [41, 42]. In patients with diabetes, self-efficacy and 
perceived autonomy support, which is a key element of MI, were associated with 
improved glycemic control, better perceived health, and self-management behaviors. 
[43-46]. This has also been shown in PKU, with positive associations between parental 
self-efficacy and perceived internal locus of control and better metabolic control in 
children with PKU [47, 48].  
Treatment adherence and subsequent metabolic control decrease with age in 
individuals with PKU [4, 49, 50]. MI has been associated with improved self-efficacy 
and health outcomes in chronic disease [35]. We hypothesize that the use of MI 
techniques will improve treatment adherence and metabolic control in a PKU clinical 
population. This study seeks to demonstrate the effectiveness of 6-month intervention 
with phone-based MI, goal setting, and a monthly summary to improve treatment 






Patients aged 7-35 years, diagnosed with PKU on newborn screening and treated 
since birth were recruited. All participants were English speaking and had Internet access 
at home. Exclusion criteria included 1) intellectual disability (IQ<70), 2) pregnancy, and 
3) concurrent participation in clinical trial(s) testing enzyme substitution therapy. 
Patients were identified and recruited through the Utah Metabolic Clinic from December 
2013 to July 2014. The University of Utah Institutional Review Board approved this 
study and written consent – and child assent, if appropriate – was obtained for all 
participants. Participants were provided financial compensation for their time.  
4.3.2 Measures 
4.3.2.1 Blood Phenylalanine 
Participants were asked to collect monthly blood Phe samples via finger stick as 
standard of care during the study. In addition to the standard monthly sample, during 
months 3 and 6, participants were asked to collect an unannounced blood Phe sample 
within 24 hours of the request. The random date was generated in Excel. All additional 
blood samples collected via finger stick during the study were also included in statistical 
analysis for the intervention Phe levels. Blood samples obtained at the baseline visit and 
up to 6 months prior to enrollment were used for the pre-intervention comparison. 
Pharmacological treatments for PKU, including a synthetic form of tetrahydrobiopterin 
(BH4) and recombinant phenylalanine ammonia lyase conjugated with polyethylene 
glycol (rAvPAL-PEG), have the potential to alter blood Phe levels independent of 




who initiated and/or discontinued BH4 (n=5) or rAvPAL-PEG (n=2) during the 6-month 
pre-intervention period. All levels included in statistical analysis were consistently on or 
off the medications listed above. Additionally, treatment guidelines and dietary Phe 
tolerance during pregnancy differ from a nonpregnant adult. Therefore, blood Phe levels 
obtained while pregnant during the pre-intervention period were also excluded from 
statistical analysis (n=1). Blood samples collected from finger sticks were analyzed at 
ARUP Laboratories in Salt Lake City, UT using tandem mass spectrometry without 
chromatographic separation. Blood Phe concentrations obtained from quantitative 
analysis of plasma amino acids collected via venipuncture were excluded as the analysis 
method differed.  
4.3.2.2 Food Frequency Questionnaire 
The Food Frequency Questionnaire (FFQ) © 2012 BioMarin Pharmaceutical Inc. 
was used to evaluate participants’ average protein intake. The accuracy of this tool for 
assessment of quantity and quality of protein was validated in a PKU clinical population 
aged 12 years and older [53]. The FFQ was used in place of 3-day food records, which 
are standard to assess dietary intake in PKU. The FFQ is a comparatively fast method to 
assess protein intake and allows quantification of protein from distinct food categories. It 
may also alleviate collection of food records as a barrier to treatment [53, 54]. This tool 
was designed to assess average protein intake from medical formula and 12 food 
categories over the preceding month in individuals following a low protein diet. Food 
categories include low protein foods, vegetables, fruits, breads and grains, snack foods, 




4.3.2.3 Stages of Change and Self-Efficacy 
The SOC questionnaire followed the format used in previous studies [55, 56] and 
is described in more detail in Chapter 3, Appendix A. We assessed current SOC for three 
behavioral domains: meeting dietary Phe/protein goals, meeting medical formula goals, 
and making healthy food choices. SOC for the healthy food choices domain is not 
described further in this study, as it has a lesser impact on blood Phe levels. For each 
domain, participants were asked to choose the behavior that was most important to them 
from a list (e.g., “Drink formula several times per day”) or could add their own behavior. 
Current SOC was assessed for the selected behaviors. For each domain, the SOC was 
scored on a progressive scale that ranged from “1” (absence of the desire to change 
behavior) to “5” (presence of the desire to maintain a changed behavior).  
Self-efficacy was measured with a modified version of the eight-item Diabetes 
Self-Efficacy Scale developed at the Stanford Patient Education Research Center [57, 
58]. Revisions were made to include self-management items relevant to PKU (described 
in Chapter 3, Appendix B). Items were ranked on a 10-point Likert scale ranging from 1 
(not confident) to 10 (totally confident); the total score averages the results of the eight 
items.  
4.3.3 Interventions 
4.3.3.1 Monthly Summary 
A monthly summary was emailed to participants to summarize previous 
responses (SOC and monthly goal). It also illustrated average protein intake over the last 
month compared to the amount prescribed and an overview of current sources of dietary 





Figure 4.1.  Monthly Summary Emailed to Participants. This summary reflects current stage of change for three behavioral 




instructions to review the information prior to the call. Participants were not required to 
view the summary during the conversation. 
4.3.3.2 Phone-Based Motivational Interviewing 
Participants were contacted by phone once per month during the 6-month 
intervention. Author Krista Viau received over 30 hours of MI training via workshops, 
individual coaching, and expert practice feedback prior to initiating the MI intervention. 
Michael Adelman, a triple board resident (pediatrics, general psychiatry, child 
psychiatry) trained in MI, reviewed a random sample of audio-recorded MI sessions with 
Krista Viau to evaluate reliability of the MI intervention and provide practice feedback. 
Calls were made after metabolic clinic staff received monthly blood Phe results, 
generally 5-10 days following sample collection. For participants less than 18 years of 
age, telephone counseling was conducted with either (1) the caregiver and participant 
concurrently or (2) participant alone followed by a verbal summary provided to the 
caregiver.  
The MI intervention differed from standard of care reporting of blood Phe results. 
The standard in our clinic generally involves relaying the laboratory values to the patient 
(or parent if the patient is less than 18 years), assessing potential requirements for dietary 
changes, and offering advice if needed. In this study, the interventionist reviewed topics 
on the monthly summary and the participant’s blood Phe levels at the beginning of the 
session. After providing this information, participants were asked if he/she would like 
tofocus on anything in particular the following month. A list of options was presented if 
the participant did not have a particular topic in mind. MI techniques aimed to 




motivation for change were used during the session to explore potential behaviors to 
target and, if appropriate, to create a monthly goal.  
4.3.3.3 Monthly Goals 
Goal setting is part of the MI planning process and should only occur when the 
participant is ready to do so [30]. Topics for goals were derived from the discussion, 
predominantly from participant change talk. Monthly goals did not always align with 
behaviors selected on the SOC questionnaire. If the participant was ready to form a 
monthly goal, the interventionist helped him/her form a specific and measureable goal 
according to guidelines [59]. Participants had the option of maintaining current health if 
they did not identify a specific goal they were ready to implement. During the following 
month’s telephone conversation, the interventionist reviewed the participant-reported 
progress of the previous month’s goal and discussed next steps.  
4.3.4 Data Collection 
Study data were collected and managed using the Research Electronic Data 
Capture (REDCap) tools hosted at University of Utah [60]. Participants were instructed 
on questionnaire completion during the in-person baseline visit. All questionnaires were 
emailed to participants and completed online using REDCap survey tools. Participants 
under 18 years of age were asked to complete the questionnaires with a caregiver. Krista 
Viau reviewed individual responses requiring clarification with participants over the 
phone. The FFQ and SOC questionnaires were administered monthly. The self-efficacy 
questionnaire was completed at baseline, month 3, and month 6. Participants were asked 
to collect the blood sample on the same day as questionnaire completion.  




electronic medical record: date of birth, sex, current protein and medical formula 
prescriptions, blood Phe results collected within 6 months prior to enrollment, and 
eligibility for an individualized education program (IEP), which suggests the presence of 
learning problems. Participants were designated as IEP eligible in this study if they had 
ever had an IEP and/or had been recommended for an IEP by a psychologist working 
within the metabolic clinic.  
4.3.5 Data Analysis 
Demographic, phenylalanine, and questionnaire data were summarized using 
descriptive statistics: continuous variables were reported as mean ± standard deviation if 
normally distributed or median and interquartile range (IQR) if not normally distributed, 
and categorical variables were reported as frequencies. Baseline SOC for both 
Phe/protein and medical formula behavioral domains (score 1-5) were summed to create 
a total SOC score ranging from 2-10. Differences in data without repeated measurements 
were assessed with Fisher’s exact test and Mann-Whitney U test.  
For the nutritional outcomes with repeated measurements within the same 
participant, a random intercept and random slope mixed effects linear regression model 
was fitted to the percentage protein consumed compared to prescribed with an 
unstructured variance-covariance structure. The predictor variables included time (days), 
intervention (baseline vs. post), and either Phe/protein SOC or medical formula SOC. 
Given that there were repeated measurements of blood Phe across time within the 
same participant, a mixed effects linear regression model was fitted to the data. The 
model was fitted with random intercepts and random slopes across time for participants 




(days), intervention (pre vs. post), and time x intervention interaction term. It also 
included two covariates, continuous baseline stage of change and IEP (eligible vs. not 
eligible).  
Statistical analyses were performed using Stata 13.0 (StataCorp, College Station, 
TX). Significance was defined as a two-sided p-value with alpha of 0.05. 
4.4 Results 
Participant enrollment and retention are described in Fig. 3.1. Participants 
completed a median of five (4-6) of the planned six phone-based MI sessions with the 
median duration of 13 minutes (10.5-16). Eleven participants were preadolescents (7-12 
years), 5 were adolescents (13-17 years), and 16 were adults (18+ years). All participants 
were prescribed a low protein diet with medical formula, though 3 participants reported 
rarely drinking medical formula at baseline. There was no significant difference in pre-
intervention Phe levels between those taking formula <3 and ≥3 times daily (p=0.71). 
While the majority of participants were in the action or maintenance SOC for behaviors 
related to metabolic control (Table 3.3), approximately half of participants’ blood Phe 
levels exceeded the recommended range at baseline (120-360 μM) [61].  
When compared to the median (IQR) Phe levels of the 37 patients who declined 
participation (319 μM (176-504)), participant median pre-intervention Phe levels were 
not significantly different (357 μM (193-573), p=0.12). However, 15 patients who 
declined participation did not have results available for comparison, as 13 patients had 
not collected blood Phe samples and two had concurrent conditions affecting Phe 
concentrations. Age distribution (preadolescent, adolescent, and adult categories) was 




female) differed between participants and nonparticipants (p<0.01). 
4.4.1 Average Protein Intake 
For all participants, the median medical formula intake was 100% (100-100%) of 
the amount prescribed, and natural protein intake was 114.3% (91.7-146.9%) of the 
amount prescribed throughout the intervention. For most, over 75% of total protein 
consumed came from medical food, and nearly 25% of natural protein came from snack 
foods (Fig. 4.2). The majority of participant responses (58.3%) to the FFQ indicated 
consuming medical formula in three or more servings per day and 10% of responses 
indicating formula intake in one serving per day. 
When compared to baseline, there was no significant difference in the percentage 
of medical formula or natural protein consumed in relation to the amounts prescribed 
during the intervention after controlling for SOC for medical formula or Phe/protein 
goals (p=0.89 and p=0.99, respectively). In the same model, SOC for medical formula 
goals was significantly associated with percentage formula consumed (β=5.4, p=0.027), 
though SOC for Phe/protein goals was not significantly associated with percentage 
natural protein consumed (p=0.12). We also included the natural protein goal in the 
dietary Phe/protein model, as the degree of dietary restriction may impact one’s ability to 
follow recommendations. Lower protein tolerance was associated with increased 
percentage of natural protein consumed compared to the goal after controlling for the 
intervention, time, and SOC (β=-3.7, p=0.015). 
4.4.2 Blood Phenylalanine Concentrations 
The median number of blood Phe samples collected in the 6 months pre-






Figure 4.2.  Median Distribution of Protein Intake for All Participants. Protein intake 
calculated with the Food Frequency Questionnaire, which estimated 
participants’ average protein intake over the last month. (A) Median 
percent of total protein intake from medical formula (phenylalanine-free 
protein) and natural protein (food). (B) Median percent of natural protein 




the pre-intervention comparison. Baseline Phe was not significantly different between 
those with pre-intervention Phe samples and those with only a baseline sample (p=0.31). 
During the course of the intervention, participants collected a median number of seven 
(6-8) blood Phe samples. 
Unannounced blood Phe samples were collected during months 3 and 6 due to the 
potential for individuals to alter dietary intake prior to collecting a blood sample [1, 2]. 
Unannounced samples were collected 15.4±4.1 days apart from the scheduled sample 
during month 3 and 13.2±6.0 days apart during month 6. The unannounced Phe levels 
collected at months 3 (n=17/27) and 6 (n=19/26) were not significantly different from the 
scheduled blood collection dates during the same month (p=0.96 and p=0.37, 
respectively). 
Change in Phe was evaluated with a mixed effects linear regression model. We 
included baseline SOC (Phe/protein and medical formula domains) and IEP eligibility in 
the model, as both were significantly associated with blood Phe slope in bivariate 
regression models (data not shown). IEP eligibility was not associated with Phe slope 
after controlling for the effect of the intervention and baseline SOC (β=132.4, p=0.12). 
Blood Phe levels increased prior to enrollment and during the intervention (Fig. 4.3A). 
The pre-intervention blood Phe slope (β=0.71) was not significantly different from the 
intervention slope (β=0.27, p=0.13). However, higher baseline SOC (β=-63.7, p=0.005) 
was significantly associated with a decrease in blood Phe slope. 
There is a known effect of age on blood Phe levels as individuals adapt to a social 
life and assume self-management responsibilities [4]. Mean pre-intervention blood Phe 





Figure 4.3.  Predicted Slope in Blood Phenylalanine (Mean ± Standard Error) 6 
Months Pre-intervention and During the Intervention. Mixed effects linear 
regression model predicted the slope after controlling for baseline stage of 
change and eligibility for an individualized education program. (A) Pre-
intervention slope for all participants (β=0.71) compared to the 
intervention slope (β=0.27) was not significantly different (p=0.13). (B) 
Pre-intervention and intervention slopes for each age category were not 
significantly different from the adult group (p=0.69 for preadolescents 





(457±236 μM), significantly differed by age group (p<0.001). Considering differences in 
mean Phe by age category, we tested a three-way interaction variable between age 
category, intervention, and time. The pre-intervention and intervention slope for blood 
Phe was not significantly different for either preadolescent or adolescent groups when 
compared to the adult group (p=0.69 and p=0.73, respectively, Fig. 4.3B). 
We also assessed the effect of changing self-efficacy scores on the blood Phe 
slope during the intervention. Baseline self-efficacy was not significantly associated with 
blood Phe slope (p=0.49) pre-intervention and during the intervention. However, after 
including all self-efficacy scores during the intervention, self-efficacy was significantly 
associated with blood Phe slope during the intervention (β=-64.5, p<0.001). We were not 
able to assess the interaction term in this model, considering self-efficacy was only 
collected at three time points (baseline, month 3, and month 6). Self-efficacy was not 
kept in the main model because it restricted our ability to compare pre-intervention and 
intervention blood Phe slopes.  
4.5 Discussion 
This study contributes to our understanding of the relationship between 
motivational interviewing and behavior change in the context of chronic disease 
management and supports the link between SOC, self-efficacy, and health outcomes. 
Practitioners have identified the need for improved education and motivational strategies 
to promote self-management behaviors in PKU [2, 5, 62-64] with a goal of maintaining 
optimal metabolic control throughout life [61]. However, few studies have explored 
methods to increase patient motivation in a PKU population [65, 66]. This is the first 




improve treatment adherence and metabolic control in participants with PKU. 
Treatment adherence was assessed based on participant-reported medical formula 
and natural protein intake, as appropriate intake of these nutrients is the foundation of 
PKU dietary management [67]. Self-management skills related to dietary treatment are 
often lacking [29], as reported in Chapter 2 with only approximately half of adolescents 
and adults with PKU reportedly preparing and consuming medical formula every day 
(n=11/22) and tracking protein intake (n=12/22). Our results did not show a significant 
change in adherence to medical food intake during the MI intervention. However, the 
majority of participants were consuming 100% of their formula prescription. Timing of 
medical formula intake is also an important factor in blood Phe control and variation 
[68]. The majority of participants consumed formula in multiple servings daily, though 
we did not see a difference in pre-intervention Phe levels between those taking formula 
<3 and ≥3 times daily.  
Adherence to natural protein prescription also did not increase during the 
intervention. We adjusted for protein tolerance in this model, and higher protein 
tolerance was associated with improved adherence to goals. The FFQ estimates of 
average protein intake have been shown to be less accurate than a 3-day food record 
(mean error rate of 7%) and do not correlate well with a singular blood Phe level [53]. 
The main purpose of using the FFQ vs. food records was to reduce barriers to collecting 
dietary information, and to illustrate total protein intake as well as the sources of dietary 
protein in order to facilitate discussion with the participant.  
The primary outcome of interest in this study was change in blood Phe levels 




during the 6 months preceding enrollment for all age categories (Fig. 4.3). This could be 
partly due to increasing age and rapid increases in Phe have been noted in adolescents 
[50]. Changes in treatment or life stages may also contribute. In our sample, 2 
participants were discontinuing rAvPAL-PEG, 1 participant was entering adolescence, 2 
were entering adulthood, and 1 participant was returning to a pre-pregnancy dietary Phe 
tolerance prior to enrollment.  
After accounting for baseline SOC and learning problems, the change in blood 
Phe levels was not significantly different during the intervention when compared to the 
pre-intervention slope (p=0.13, Fig. 4.3). It is possible that behavioral changes required 
to decrease blood Phe levels would require a longer follow-up period. In addition to the 
amount of effort and motivation required to initiate and maintain behavior change, 
achieving good metabolic control requires multiple behaviors. For example, if someone 
starts keeping food records but does not drink formula regularly, they are progressing but 
it may not make a substantial impact on blood Phe levels. There are also several factors 
that influence a blood Phe result unrelated to treatment adherence, including illness, 
growth, and diurnal variation [69-72].  
Baseline SOC for Phe/protein and medical formula goals was significantly 
associated with change in blood Phe levels over time. Research in asthma and physical 
activity has demonstrated an increase in SOC with MI interventions [73, 74], which may 
then facilitate behavior change [75]. Our results are consistent with a previous report 
summarizing three randomized controlled trials showing an association between higher 
baseline SOC for fat intake and progression towards action over 12-24 months in 




completion of a 4-month intervention was negatively associated with baseline Phe levels 
(r=0.49), which may be related to baseline SOC [65]. Evaluating SOC for behaviors 
contributing to metabolic control may be useful in a clinical setting to quickly determine 
readiness to change and to tailor recommendations accordingly.  
While the three age groups had different mean Phe levels, the change in blood 
Phe slope pre-intervention and intervention was not significantly different between age 
categories (Fig. 4.3B). This suggests the intervention was not more effective in one age 
category. The majority of MI research has been conducted with adolescents and adults, 
and interventions involving children typically involve both parents and children [37]. 
MI’s focus on supporting autonomy may be particularly effective in adolescents to help 
resolve ambivalence and increase self-efficacy [18, 77]. However, more research is 
needed to explore the effect of MI among different ages. 
Previous studies have demonstrated an association between self-efficacy and 
behavior change across a multitude of domains, and MI may be a means to increase self-
efficacy for target behaviors [35, 41-47, 78]. Our results indicate increasing self-efficacy 
for PKU management behaviors was significantly associated with a decrease in blood 
Phe levels. Self-efficacy is particularly important considering the multiple behaviors 
needed to achieve appropriate blood Phe levels. There is evidence suggesting 
participation in one self-management behavior increases the chance of participation in 
other behaviors, possibly due to achieving mastery in one area that translates elsewhere 
[79, 80]. Strategies aimed to increase mastery experiences, such as goal setting and 
action planning may be beneficial to increase self-efficacy and reduce blood Phe levels.  




function deficits in PKU [16, 81]. While we did not see an association with slope in 
blood Phe and learning problems after controlling for other factors, intellectual and 
executive deficits have been associated with decreased self-management behaviors in 
other chronic diseases [11, 82]. Due to the potential for these deficits, individuals with 
PKU may need additional help to adopt recommended self-management skills and 
achieve therapeutic blood Phe levels. Additionally, IEP eligibility is only a proxy for 
learning impairment and more thorough assessment of cognitive deficits may be 
warranted to further explore this relationship.  
MI may be beneficial with a PKU population for several reasons. The treatment 
for PKU is complex, but regardless of the existing skillset, MI may be used to further 
develop motivation for chronic disease management. MI has been used effectively as the 
sole intervention to elicit intrinsic motivation to change and also as a method of engaging 
patients in other educational programs. It is an ideal tool to help patients prioritize in the 
face of competing obligations, as it allows practitioners to elicit values and topics of 
importance from the patient (e.g., potential ramifications of the diet on social life), which 
increases rapport and can lead to productive discussion. Lastly, consequences of elevated 
Phe levels accumulate over time and are not always apparent to the individual [5, 17]. MI 
can help address this by developing discrepancy between values and behaviors [30].  
We propose MI is feasible for PKU patients followed by outpatient metabolic 
clinics despite potential barriers, such as time constraints and training processes. MI can 
be successfully delivered in a single session or in several shorter sessions [35]. Research 
has shown positive outcomes with brief MI interventions [83, 84], and brief MI has been 




phone-based MI intervention was designed to be accessible for patients who do not live 
locally, a commonality among many metabolic centers [85, 86]. Several studies have 
demonstrated benefits of phone-based MI interventions to improve SOC and health 
behaviors [74, 84, 87, 88]. Additionally, while MI started with interventionists trained in 
psychology, the delivery of MI has expanded to a variety of healthcare providers, 
including physicians, dietitians, and nurses [37, 89]. Considering the primary treatment 
for PKU is nutrition therapy, in our study, a metabolic dietitian delivered the phone-
based MI intervention. 
The training process is a common barrier to implementation, considering the 
amount of training required to become proficient in MI [90, 91]. While acquiring MI 
skills takes time, training practitioner(s) within a metabolic clinic may be worth the 
investment considering its association with positive health outcomes. Additionally, there 
is some evidence that simply adopting the MI spirit (collaboration, evoking the patient’s 
own motivation, and honoring autonomy) and reducing MI nonadherent behaviors 
(confronting, giving advice without permission, and giving orders or imperatives) have 
been associated with positive outcomes [78, 92]. This suggests practitioners can have a 
positive impact in a clinical setting by implementing MI principles.  
Additional research is needed to evaluate the impact of MI to improve adherence 
and metabolic control in a PKU population. A multicentered trial evaluating the MI is 
warranted in order to enroll an adequate sample size for a controlled trial considering 
PKU is a rare disease. Longer intervention and follow-up are also recommended. It may 
take longer than 6 months to achieve a significant difference in blood Phe levels, and the 





Several factors may have affected our ability to evaluate the efficacy of the MI 
intervention. Our sample size was small (n=31), which reduces the power to detect 
significant associations. However, PKU is a rare disease, and the original patient pool 
(n=183) comprised all known patients with PKU in Utah and a portion from surrounding 
states. Due to the rarity of PKU, participants acted as their own control in the before-and-
after study design, which limited our ability to control for the effect of increased 
observation on treatment adherence. We collected two unannounced blood Phe samples 
to help address this and the potential for participants to alter dietary intake in the days 
prior to a blood sample, which were not significantly different from scheduled Phe 
samples. 
There was potential for selection bias, considering we had a number of 
individuals lost to follow up (n=26) and declining participation (n=37). Nearly all of our 
participants were currently drinking medical formula, which may not be representative of 
most individuals with PKU, especially adults. Additionally, it was difficult to compare 
blood Phe levels between our sample and those declining participation, as approximately 
40% of patients did not have Phe levels available for comparison. However, recruitment 
included mailing flyers to last known addresses and advertising on Facebook through a 
local PKU community to reach those who were not attending clinic regularly.  
The questionnaires were altered or were not administered in the same manner as 
their original use. Our measures of SOC and self-efficacy were altered to reflect 
meaningful statements to individuals with PKU. We measured average protein intake 
over the last month with an FFQ that participants completed online. This tool was 




Participants were contacted to clarify responses after FFQ completion, but we were 
unable to determine if FFQ online administration was as accurate as in-person 
administration. Lastly, the results of the FFQ were emailed to participants as a monthly 
summary (Fig. 4.1), though we were unable to assess if participants viewed the summary 
sheet and if it contributed to the effect of the intervention. 
4.5.2 Conclusion 
Phone-based motivational interviewing, delivered by a metabolic dietitian, with 
monthly goal setting is feasible for clinical use in patients with PKU. There was no 
significant change in dietary adherence or blood Phe slope during the intervention. 
Higher baseline SOC for Phe/protein and medical formula goals was significantly 
associated with lower blood Phe levels. Additionally, increasing self-efficacy scores 
were significantly associated with improved metabolic control. It is possible that a longer 
follow up period is needed to demonstrate change in blood Phe levels. However, it is 
encouraging to see inverse associations between SOC, self-efficacy, and metabolic 
control in PKU, as these intermediate outcomes may be targets of future behavioral 
interventions. Additional research is warranted to further evaluate MI in a larger sample 
size and a longer duration of follow-up to further explore the utility of MI in this 
population.  
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Phenylketonuria (PKU) requires lifelong treatment with strict dietary control of 
phenylalanine (Phe) or protein intake with supplemental medical formula to avoid 
sequelae of inadequately treated PKU, including subtle intelligence and executive 
functioning deficits, slowed processing speed, psychological and behavioral problems, 
and poor nutrient intake [1-6]. Unfortunately, PKU patient adherence to treatment goals 
begins to decrease after early childhood with subsequently elevated blood Phe levels [7-
9]. Concomitantly, self-management skills are often not transitioned from parent to child 
at an early age, resulting in a suboptimal skillset in adolescents and adults [10]. 
Compared to the plethora of research demonstrating the link between elevated blood Phe 
levels and brain dysfunction [3-5, 11-18], relatively few studies have assessed strategies 
to support development of self-management skills to enable treatment adherence in PKU 
populations [19-22]. This body of research indicated that: 
1. Self-management skills and treatment knowledge in patients with PKU aged 
7-30 years were generally less than clinically recommended and did not 
consistently increase with age. Additionally, in our small sample, report of 
using more self-management skills and accurate treatment knowledge were 




2. Adolescent and adult participants of a 6-month intervention with phone-based 
motivational interviewing (MI) and goal setting demonstrated a significant 
increase in self-efficacy for PKU self-management skills. Presence of 
learning problems was not associated with lower self-efficacy.  
3. Higher self-efficacy and baseline readiness to change were associated with 
lower blood Phe levels during the phone-based MI intervention. Our results 
suggest MI is feasible with a PKU population.  
There are many barriers to developing self-management skills and adhering to 
recommended therapies in individuals with PKU and other chronic conditions. Treatment 
nonadherence in PKU may reflect lack of immediate symptoms reducing motivation to 
adhere to daily therapies [12], increasing manifestation of cognitive and psychological 
impairments that develop over time [12], an artifact of current developmental phase (e.g., 
adolescence) [23], poor transition of self-management responsibilities, and/or decreasing 
motivation for self-care in the face of competing obligations. Additionally, current health 
systems may not adequately support patient adherence to recommended therapies.  
Routine measures to support development of self-management skills are needed 
for patients with PKU. In our clinic, the self-management questionnaires acted as a 
checklist for anticipatory guidance. Review of the questionnaires allowed providers to 
easily evaluate current skills and knowledge and facilitate discussion with families on the 
primary topics of self-management in an outpatient clinical setting. MI techniques also 
have the potential to increase motivation to initiate and/or maintain behavior change to 
prevent negative health outcomes in PKU and other chronic conditions.  




of the MI intervention, it was apparent modified questionnaires and techniques were 
needed in the preadolescent age group compared to older participants. Considering the 
degree of parental assistance at this age, interventions targeting both the patient and 
parent are recommended. Developing self-management skills remains critical in this age 
group, as ability to assume responsibility for self-care increases, and it provides 
opportunity to instill self-management skills before facing increased independence over 
food choices during adolescence and adulthood. 
Our results suggested MI would be a viable option for individuals with PKU with 
or without learning problems. Fundamental features of PKU include subtle intellectual 
deficits with more pronounced executive function deficits [13], which have been 
proposed to be a substantial barrier to following the dietary regimen [24]. MI has been 
used in other populations with cognitive/executive functioning issues [25-27] and 
methods to adapt MI for those with mild intellectual disability have recently been 
explored [28]. Additionally, combining goal setting/action planning with MI may help 
patients with executive deficits problem solve and carry out a behavior once they are 
motivated to take action. Collecting a robust cognitive and executive evaluation at 
baseline would provide a means to evaluate MI at varying levels of cognitive 
impairment. Further evaluation would be required for use of MI with individuals with 
PKU and intellectual disability, an exclusion criterion for the current studies.  
The use of MI with individuals with PKU deserves further exploration. The 
studies described here are merely an introductory evaluation of MI in a PKU population. 
Therefore, the opportunities for research assessing MI and other strategies to support 




reevaluated with a randomized study design and larger sample size, which would have 
alleviated many of the limitations of the current studies. Extending the duration of the 
intervention and/or follow-up is also recommended to see if change in Phe levels 
requires more time to occur and if the effects of the intervention are maintained. The 
studies presented here also highlight a need for validated tools to assess self-
management, SOC, or self-efficacy in a PKU population.  
We recommend evaluating MI in subgroups of patients with PKU and other 
inborn errors of metabolism. In preadolescents, an MI intervention could be used with 
both parents and children to increase engagement in self-management programs. At this 
age, learning impairment may not yet be apparent [12], which may reduce motivation for 
both parents and children to maintain adherence to the strict diet. Additionally, the 
patient-centered focus of MI may appeal to older patients who are returning to clinic 
and/or to help prevent loss to follow up, which is a substantial issue in the adult PKU 
population [29]. Lastly, exploration of MI and other strategies to support self-
management in a PKU population could be applied to other inborn errors of metabolism, 
many of which share treatment principles and are also treated at metabolic centers.  
This body of research explored methods to prevent negative consequences of 
inadequate self-management and treatment adherence. Public health aims to prevent 
disease and promote health for the population. PKU is an exemplar of the difficulties 
associated with improving self-management and treatment adherence in populations 
affected with a lifelong, genetic disease. We cannot readily prevent the occurrence of 
PKU, as it is a genetic condition; however, early identification and treatment through 




intellectual disability. Additionally, there is potential to prevent or reduce the negative 
outcomes associated with inadequately treated PKU. While we studied a rare disease, the 
results offer implications for the health care system caring for this population and other 
inborn errors of metabolism. 
The results of this dissertation suggest MI is a feasible, potentially beneficial 
counseling style to use with individuals with PKU. Participants’ self-management skills 
were less than clinically recommended and did not consistently increase with age. MI 
with goal setting and a monthly summary was associated with increased self-efficacy 
regarding PKU management, and increased self-efficacy was associated with an 
improvement in metabolic control. While the executive deficits and behavioral aspects of 
PKU add another layer of complexity to treatment adherence, methods to support self-
management and increase motivation for behavior change are still necessary. 
Motivational interviewing has potential to increase motivation and confidence to engage 
in self-management behaviors in a PKU population. 
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 APPENDIX A 
 
 
COMPOSITION AND CODING FOR SELF-MANAGEMENT 
 






 BEHAVIOR SCALE – POTENTIAL SCORE 0-2 
10-12 Years  13-17 Years  18-30 Years  
Do you help prepare your 
formula or even prepare it 
by yourself? 
-I weigh/mix my formula 
myself every day (7 days per 
week). 
-I weigh/mix my formula 
myself most days (4-6 days 
per week).  
-I weigh/mix my formula 
myself sometimes (≤ 3 days 
per week).  
-I help my parents weigh/mix 
my formula. 
-My parents weigh/mix my 
formula every day. 


















Do you prepare your own 
formula?  
 
-I weigh/mix my formula myself 
every day (7 days per week). 
-I weigh/mix my formula myself 
most days (4-6 days per week).  
-I weigh/mix my formula 
sometimes (≤ 3 days per week).  
-My parents weigh/mix my 
formula every day. 
















Do you prepare and drink 
your formula regularly? 
-I prepare and drink my formula 
every day (7 days per week). 
-I prepare and drink my formula 
most days (4-6 days per week). 
-I prepare and drink my formula 
sometimes (≤ 3 days per week). 
-No, I do not prepare my 
formula but I drink it. 















Have you tried pricking 
your own finger to get a 
blood sample? 
-Yes, I am an expert! 
-Yes, I have tried it 1-2 times.  








Do you collect your own finger 
stick blood samples at home? 
-Yes, I always collect my finger 
stick sample myself.  
-Yes, I sometimes collect my 
finger stick sample myself. 
-Yes, but I still need some help 
from my parents. 
-No, but I know how to collect a 
finger stick sample. 
-No, I have never tried it. 















Do you collect your own finger 
stick blood samples at home? 
-Yes, I collect them at least 
monthly (12+ times per year). 
-Yes, I collect them at least 
every other month (6-11 times 
per year). 
-Yes, I collect them every once 
in a while (≤5 times per year). 
-No, but I know how to collect a 
finger stick sample. 






















KNOWLEDGE SCALE – POTENTIAL SCORE 0-3 
7-12 Years  13-17 Years  18-30 Years  
What is your formula 
prescription?  
-Correct 







What is your formula 
prescription?  
-Correct 







What is your formula 
prescription?  
-Correct 







What is your daily 
PHE/protein prescription?  
-Correct 







What is your daily 
PHE/protein prescription?  
-Correct 







What is your daily 
PHE/protein prescription?  
-Correct 







What is your goal range for 
blood PHE levels?  
-Correct 





What is the recommended blood 
PHE range for you?  
-Correct 





What is the recommended blood 
PHE range for you?  
-Correct 
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We would like to know what you think is most important to help you meet your personal 
health goals. Please choose the items that are most important to you at this time. Keep in 
mind that it does not have to be something you are currently doing. 
 
Phe/Protein Goals 
What do you think is the single most important thing you could do to meet your 
PHE/PROTEIN GOALS? Please select one. 
Count how much Phe/protein I eat  
Keep diet records  
Plan meals beforehand  
Watch my portion sizes 
Prepare meals at home  
Other (please specify) 
 




Please mark the following statement that best applies to you. 
No, and I do not plan to make this change.  
No, but I plan to make this change in the next 6 months.  
No, but I plan to make this change in the next 30 days. 
Yes, I have been making this change for LESS than 6 months.  
Yes, I have been making this change for MORE than 6 months. 
 
Formula Goals 
What do you think is the single most important thing you could do to meet your 
FORMULA GOALS? Please select one. 
Drink all formula every day  
Drink formula several times per day  
Make my own formula  
Bring my formula to school/work  
Try a different formula or try to improve the taste of my current formula  
Other (please specify) 
 




Please mark the following statement that best applies to you. 
No, and I do not plan to make this change.  
No, but I plan to make this change in the next 6 months.  
No, but I plan to make this change in the next 30 days. 
Yes, I have been making this change for LESS than 6 months.  







What do you think is the single most important thing you could do to MAKE HEALTHY 
FOOD CHOICES? Please select one. 
Eat more fruits/vegetables  
Drink fewer sweetened drinks (soda, juice)  
Eat out less often (restaurants, fast food)  
Eat fewer "junk foods" (chips, cookies, candy)  
Cook meals at home more often  
Other (please specify) 
 




Please mark the following statement that best applies to you. 
No, and I do not plan to make this change.  
No, but I plan to make this change in the next 6 months.  
No, but I plan to make this change in the next 30 days. 
Yes, I have been making this change for LESS than 6 months.  
Yes, I have been making this change for MORE than 6 months. 
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COMPARISON OF ORIGINAL SELF-EFFICACY SCALE TO 
 





We would like to know how confident you are in doing certain activities. For each of 
the following questions, please choose the number that shows how confident you are 
that you can do these tasks regularly at this point in time where 1 = not confident at all 
and 10 = totally confident. 
 
Original Scale Revised Scale 
1. How confident do you feel that you 
can eat your meals every 4 to 5 
hours every day, including breakfast 
every day? 
2. How confident do you feel that you 
can follow your diet when you have 
to prepare or share food with other 
people who do not have diabetes? 
3. How confident do you feel that you 
can choose the appropriate foods to 
eat when you are hungry (for 
example, snacks)? 
4. How confident do you feel that you 
can exercise 15 to 30 minutes, 4 to 5 
times a week? 
5. How confident do you feel that you 
can do something to prevent your 
blood sugar level from dropping 
when you exercise? 
6. How confident do you feel that you 
know what to do when your blood 
sugar level goes higher or lower 
than it should be? 
7. How confident do you feel that you 
can judge when the changes in your 
illness mean you should visit the 
doctor? 
8. How confident do you feel that you 
can control your diabetes so that it 
does not interfere with the things 
you want to do? 
1. How confident do you feel that you 
can do all the things necessary to 
manage your condition on a regular 
basis? 
2. How confident do you feel that you 
can follow your diet when you have 
to prepare or share food with other 
people who do not have PKU? 
3. How confident do you feel that you 
can choose the appropriate foods to 
eat when you are hungry (for 
example, snacks)? 
4. How confident do you feel that you 
can poke your finger to collect a 
blood sample every month at a 
minimum? 
5. How confident do you feel that you 
can do something to prevent your 
blood phenylalanine levels from 
increasing? 
6. How confident do you feel that you 
know what to do when you blood 
phenylalanine level goes lower or 
higher than it should be? 
7. How confident do you feel that you 
can judge when changes in your 
illness mean you should visit the 
doctor? 
8. How confident do you feel that you 
can control your PKU so that it does 
not interfere with the things you 
want to do? 
 
 








Figure D.1.  Summary Sheet Emailed to Each Participant Monthly Prior to the Phone-Based MI Intervention. Information includes 
current stage of change for selected behaviors, monthly goal, prescribed protein and protein consumed over the last 
month based on results of the FFQ.  
 
